Redox control of liver function in health and disease by Marí, Montserrat et al.
COMPREHENSIVE INVITED REVIEW
Redox Control of Liver Function in Health and Disease
Montserrat Marı´,1 Anna Colell,1 Albert Morales,1 Claudia von Montfort,1
Carmen Garcia-Ruiz,1 and Jose´ C. Ferna´ndez-Checa1,2
Abstract
Reactive oxygen species (ROS), a heterogeneous population of biologically active intermediates, are generated as
by-products of the aerobic metabolism and exhibit a dual role in biology. When produced in controlled con-
ditions and in limited quantities, ROS may function as signaling intermediates, contributing to critical cellular
functions such as proliferation, differentiation, and cell survival. However, ROS overgeneration and, particu-
larly, the formation of specific reactive species, inflicts cell death and tissue damage by targeting vital cellular
components such as DNA, lipids, and proteins, thus arising as key players in disease pathogenesis. Given the
predominant role of hepatocytes in biotransformation and metabolism of xenobiotics, ROS production con-
stitutes an important burden in liver physiology and pathophysiology and hence in the progression of liver
diseases. Despite the recognized role of ROS in disease pathogenesis, the efficacy of antioxidants as therapeutics
has been limited. A better understanding of the mechanisms, nature, and location of ROS generation, as well as
the optimization of cellular defense strategies, may pave the way for a brighter future for antioxidants and ROS
scavengers in the therapy of liver diseases. Antioxid. Redox Signal. 12, 1295—1331.
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I. Introduction
Free radicals were first documented about 50 years agoin plant and animal tissues by using paramagnetic reso-
nance absorption techniques (62). Despite this seminal find-
ing, free radicals were considered mainly as mediators of the
damaging effects of radiation, with little interest in biology,
until McCord and Fridovich (210) described the existence of a
specific enzyme dedicated to scavenge the superoxide anion
(210). The landmark discovery of superoxide dismutase
(SOD), *15 years ago, sparked a considerable interest in the
chemistry and biology of free radicals, now being recognized
as critical players in multiple cellular functions, diseases, and
aging. Free radicals, including reactive oxygen=nitrogen
species (ROS, RNS), are generated as by-products of bio-
chemical reactions within cells and, hence, considered as
inherent intermediates of many physiologic processes. How-
ever, when produced in large amounts or in an uncontrolled
fashion, free radicals inflict tissue damage and are implicated
in many pathologic processes. The understanding of the fine
balance between the physiologic and pathologic effects of free
radicals is an important driving force in this field of research
that may have an impact on diverse disciplines, including
physiology, cell biology, and clinical medicine.
One of the predominant foundations for the biologic ac-
tions of free radicals and reactive species lies in cellular redox
signaling, which involves the posttranscriptional modifica-
tion of proteins that use redox chemistry. A redox reaction
involves the transfer of electrons between two molecules or
atoms, resulting in their reduction (gain of electrons) and
oxidation (loss of electrons). The paradigm of a redox reaction
in cell signaling is illustrated by the reduction=oxidation state
of cysteine residues of proteins, resulting in the breaking
down or formation of a protein disulfide bond. Redox changes
of target proteins are initiated by the generation of ROS and
RNS, which can lead to the formation of disulfide bridges
between two adjacent cysteine residues in a protein or the
generation of S-nitrosothiols, resulting from the attack of
nitric oxide or peroxynitrate on cysteine. In addition, methi-
onine residues of proteins can be oxidized by ROS to methi-
onine sulfoxide, which is specifically repaired by methionine
sulfoxide reductases A and B (267). Interestingly, this partic-
ular modification of methionine residues is thought to serve
as a free radical sink, thereby protecting other macromole-
cules from oxidation. Consistent with this view, the specific
lack of methionine sulfoxide reductase A increases sensitivity
to oxidative stress in mice (267). These thiol modifications can
be regulated by factors that act on or modulate ROS=RNS
generation.
Besides proteins, free radicals and ROS also target other
cellular components, including DNA and lipids, whose oxi-
dative modifications can alter signaling pathways and trigger
cell death. Although ROS are produced in many cell types
and recognized in the pathogenesis of different diseases (86,
326), given the bulk of the liver in the biotransformation of
xenobiotics and metabolism, in the present review, we focus
mainly on the role of ROS and redox control of liver func-
tion in health and disease. Although some aspects of the
chemistry and impact of free radicals have been previously
reviewed (272, 274), in the following sections, we briefly de-
scribe some basic notions about their nature, sources, and
defense.
II. Free Radicals and Reactive Species:
Sources and Defense
Free radicals are molecules or atoms with unpaired elec-
trons, making them highly reactive and extremely likely to
take part in a chemical reaction. Generally, radicals can be
formed by homolytic bond cleavage, usually between two
atoms of similar electronegativity (often O-O or O-N bonds),
or by single-electron oxidation or reduction of an atom or
molecule (e.g., superoxide anion). In addition, to this one-
electron radical, two-electron oxidants, although not strictly
radicals, arise from the metabolism or scavenging of the
former, as best exemplified by the generation of hydrogen
peroxide from superoxide anion. Within each class, some are
much more reactive or strongly oxidizing than others, a prop-
erty that can be estimated by the one-electron reduction po-
tential, given that the activation energy for radical reactions
is low. The reduction potential (in volts) is a measure of the
affinity of a substance for electrons compared with that of hy-
drogen, which is set at 0 (e.g., reduction potentials for super-
oxide anion, hydrogen peroxide, and hydroxyl radical are
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0.94, 0.32, and 2.31V, respectively). Molecules that have lower
reduction potentials are strongly electronegative and can ox-
idize. Among biologically relevant ROS, hydrogen peroxide
has the lowest reactivity, the highest stability and intracellular
concentration, and hence is highly regulated in cells to avoid
its overgeneration (117).
A. Sources of ROS
1. Extramitochondrial. Biologic systems are constantly
exposed to intrinsic and extrinsic sources of free radicals and
reactive oxidants. Although in most cell types, ionizing and
UV radiation are important sources of free radicals, in the
liver, these species arise as by-products of the metabolism of a
wide range of drugs and xenobiotics (e.g., phenols, aromatic
amines) and, especially in the mitochondrial oxidative phos-
phorylation, as detailed later. The biotransformation of xe-
nobiotics (e.g., quinones) through redox cycling generates
superoxide anion. In this process, the parental compound is
reduced by a flavoenzyme such as cytochrome P450 reductase
to a radical that then reacts with oxygen to form superoxide
anion (237, 238). This reaction has been commonly used to
produce superoxide anion in in vitro conditions (63, 64). Free
radicals and ROS can be generated by various enzymes and in
different cellular locations. For instance, amino acids oxi-
dases, cyclooxygenase, lipooxygenase, nitric oxide synthase,
and xanthine oxidase, generate superoxide anions and other
derived ROS in the cytosol. Whereas cyclooxygenase and
lipooxygenase may link superoxide anion generation to ara-
chidonic acid metabolism and inflammation, with important
implications in pathogenesis and cancer, xanthine oxidase
has been involved in ischemia=reperfusion injury and liver
transplantation. Moreover, nitric oxide generated by nitric
oxide synthase can interact with superoxide anion, resulting
in the formation of the potent oxidant peroxynitrite, which in
turn can target protein cysteine thiols (see later). Oxidants
also are generated by sulfhydryl oxidase in the endoplasmic
reticulum (ER) during protein folding and disulfide bond
formation necessary for the assembly and secretory pathway
for proteins (144), as well as in peroxisomes by peroxisomal
oxidase. Of particular relevance in both liver physiology and
pathophysiology is the burst of superoxide anion formed
by NADPH oxidase. Although NADPH oxidase was first
described in professional phagocytes of the innate immune
system (e.g., neutrophils and macrophages), it is now known
that its expression is ubiquitous. The burst of superoxide
anion generated from NADPH as an electron donor and
molecular oxygen is considered a first line of defense against
ingested pathogens (254). However, NADPH oxidase has
been involved in many pathologic processes including
cardiovascular disorders and liver diseases (36, 79). A non-
phagocytic form of NADPH oxidase has been demonstrated
in vascular cell types (322). Like the phagocytic respiratory
burst NADPH oxidase, nonphagocytic NADPH oxidase re-
duces molecular oxygen to superoxide, which is in turn con-
verted to hydrogen peroxide. However, unlike the phagocytic
type, the NADPH oxidase present in blood vessels is consti-
tutively active, producing relatively low levels of ROS under
basal conditions; however, in response to peptide hormones,
such as angiotensin II (AngII), it can generate high levels of
oxidants. Both the phagocytic and nonphagocytic oxidases
are multimeric enzymes composed of plasma membrane–
associated proteins as well as cytosolic factors (317). Recently,
several smooth muscle cell homologues of gp91phox, termed
Nox (nonphagocytic oxidase), have been identified (47). Stu-
dies in liver fibrogenesis demonstrated that NADPH oxidase
mediates the actions of AngII on hepatic stellate cells and
plays a critical role in liver fibrogenesis (16). Consistent with
this function, recent data provided evidence that the disrup-
tion of the AngII-receptor type 1 extends longevity in mice,
which is associated with reduced oxidative damage, pre-
served mitochondrial integrity, and upregulation of survival
genes nicotinamide phosphoribosyltransferase (Nampt) and
sirtuin 3 (Sirt3) (20). Hence, these findings point to a func-
tional link between the renin-angiotensin system andNADPH
oxidases in the modulation of oxidative stress and its associ-
ated comorbidities, including aging.
2. Mitochondrial. In addition to the preceding pathways,
mitochondria are the largest source of ROS within cells (11).
The partial reduction of oxygen during oxidative phosphor-
ylation generates the superoxide anion, which acts on the
matrix side of mitochondria where it is then transformed
into other species, including hydrogen peroxide (88, 95, 130)
(Fig. 1). The basal production of ROS from the mitochondrial
electron-transport chain is low, with estimates of 2–4% of
electrons leaking from the electron flow to molecular oxygen
to form superoxide anion, although recent determinations
have reduced this figure to *0.1–0.5% (17). Recent data de-
scribed the onset of superoxide flashes originating from the
mitochondrial permeability transition pore that occur ran-
domly in space and time with all-or-none properties (320).
Superoxide flashes are triggered by a functional coupling
between the mitochondrial permeability transition pore acti-
vation and electron-transport chain–dependent superoxide
production, which drive localized redox signaling in indi-
vidual mitochondria under physiologic conditions. However,
when produced in an uncontrolled fashion and with in-
creased frequency, superoxide flashes contribute to global
oxidative stress, playing a key role in hypoxia=reoxygenation
FIG. 1. Mitochondrial ROS generation and defense. Mito-
chondria are the major producers of ROS, in particular,
superoxide anion, as a side effect of electron flow in the re-
spiratory chain, principally from complex I and III. In addi-
tion, hydrogen peroxide can be generated by the adaptor
protein p66Shc. The antioxidant defense includes a number
of enzymatic systems as shown, as well as the GSH redox
cycle, to prevent escalating effects through formation of hy-
droxyl radical that could target proteins, lipids, and DNA.
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injury (320). The precise site, however, within the mitochon-
drial electron-transport complexes responsible for the ROS
formation is not well established. Recent data pointed to the
flavin mononucleotide group of complex I as an important
source of ROS through reverse electron transfer (185), as in-
ferred from the ability of diphenyleneiodonium to inhibit
succinate-supported ROS generation without affecting the
flavin group of complex II. In addition, although ROS can
activate caspases, resulting in cell death (see later), active
caspases, such as caspase-3 have been described to disrupt
electron-transport complexes I and II, which contribute to the
loss of DCm and ROS generation (257), establishing a vicious
cycle. Moreover, complex III of respiration is also known to be
an important source of ROS generation (26, 110). Respiratory-
chain complex III has two ubiquinone-reactive sites: the Qo,
where ubiquinol is oxidized by redox-reactive centers, cyto-
chrome c1, and the Rieske [2Fe–2S] protein, and the Qi, where
ubiquinone is reduced by the redox center cytochrome b. The
Rieske cluster is a mobile structure, and this mobility may
facilitate rapid electron transfer between cytochrome b and c1
(148). Besides this predominant mechanism, the redox activ-
ity of p66Shc within mitochondria has been shown to gener-
ate hydrogen peroxide in the absence of superoxide anion
through oxidation of cytochrome c (116). Furthermore, puri-
fied apoptosis-inducing factor (AIF) exhibits aNADHoxidase
activity, which generates ROS, including superoxide anion
and hydrogen peroxide (77, 215). However, given the role of
AIF in cell death, it is unclear whether this emerging func-
tion of AIF as a ROS-generating enzyme contributes to the
mitochondria-dependent apoptosome activation.
In analogy to the interaction between NO and superoxide
anion in extramitochondrial compartments, mitochondrial
nitric oxide synthase (mtNOS) has been shown to generate
NO, hence constituting an important source of mitochondrial
peroxynitrite, whose impact on redox-regulated processes,
such as proliferation or mitochondrial dysfunction, depends
on the extent of generation (33). However, although the ex-
istence of mtNOS has been described in the last decade in
mitochondrial fractions isolated from different sources, recent
evidence in ultrapurified rat liver mitochondria by using in-
dependent and complementary methods to detect nitric oxide
synthase has questioned the existence of mtNOS (314). These
carefully performed studies thus refute previous claims
regarding the existence of mtNOS (at least in rat liver) and
hence the in situ generation of NO within mitochondria,
minimizing the possibility for themitochondrial generation of
peroxynitrite. In light of these new findings and considering
that NO is freely diffusible across membranes, it is con-
ceivable that the mitochondrial production of peroxynitrite
derives from the extramitochondrial NO diffusing into mito-
chondria to react with superoxide anion generated by the
electron-transport chain.
B. Cellular defense
Despite the constant generation of free radicals and oxidant
species, living organisms not only have adapted to an un-
friendly coexistence with these potentially toxic species, but
also have developed mechanisms for the advantageous use of
them. The arsenal of cellular defenses to control the magni-
tude of ROS generation is extensive and includes enzymatic
(superoxide anion dismutases, catalases, GSH peroxidases,
peroxiredoxins, glutaredoxins, thioredoxins, sulfiredoxins)
and nonenzymatic antioxidants (vitamins A, C, and E, GSH,
urate, bilirrubin). The coordinated action of antioxidant
enzymes ensures efficient ROS removal. For example, the
superoxide dismutases (SODs) catalyze the dismutation of
superoxide anion into hydrogen peroxide, which, in turn,
is converted into water and oxygen by GSH peroxidases
and catalase. Considering the reactivity and site localization
where free radicals and ROS are generated within cells, en-
zymatic antioxidant defenses are compartmentalized to neu-
tralize these species more efficiently. For instance, SOD is
localized in the cytosol (Cu=Zn SOD) or in the mitochondria
(Mn-SOD), thus handling different pools of superoxide anion
generated extra- or intramitochondrially. In addition, extra-
cellular SOD (ecSOD) is found predominantly in the extra-
cellular matrix and is known to regulate endothelial cells by
preventing NO from reacting with superoxide anion (102).
Glutathione peroxidase (GSHPx), catalase, and peroxiredox-
ins control the fate of hydrogen peroxide produced from su-
peroxide anion. Similar to ecSOD, GSHPx has also been found
in plasma. GSHPx-1, a selenoprotein, is found in the cytosol
and mitochondria of all cell types, whereas distinct peroxir-
edoxins can be located in the cytosol (Prx) or mitochondria
(Prx-III) (42, 132). These couples are associated with thior-
edoxins (Trxs) and thioredoxin reductases (TRs) in the cytosol
(Trx1=TR1=Prx) and mitochondria (Trx2=TR2=Prx-III) to re-
generate oxidized Prx (Fig. 2) (134, 256). In addition to the
disulfide-bond formation in Prx from cysteinyl thiols as a
result of hydrogen peroxide reduction, Prx can be inactivated
through the oxidation of the active cysteine into sulfinic acid
(Cys-SO2H; see later), which is efficiently reduced specifically
by sulfiredoxins (Srxs) but not by Trxs (327, 331). Srx regen-
erates inactive 2-Cys Prx, returning it to the catalytic cycle and
preventing its permanent oxidative inactivation by oxidative
stress. Regarding the role of Srxs in maintaining active Prx-III,
it is interesting to note that they reside in different cellular
sites, Srx in the cytosol and Prx-III in mitochondria, thus ques-
tioning the significance of Srxs in regenerating the hyper-
Prx
HS      SH
Prx
Cys     
Prx
S      S
H2O2
Trx
SH
Trx
NADPH+H+
NADPH+
Trx
reductase
Trx
S     S
 SH
SOH
FIG. 2. Peroxiredoxin=thioredoxin couple. Peroxiredoxins
(Prxs) are known to detoxify hydrogen peroxide, thus pro-
tecting proteins, which results in Prx oxidation with the
formation of disulfide bonds. The reduction of oxidized Prx
occurs by thioredoxins (Trxs), which are subsequently re-
duced by Trx reductase by using NADPH.
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oxidized mitochondrial Prx-III in vivo (42, 236, 328). Recent
findings, however, indicate that Srx translocates to mito-
chondria in response to oxidative stress to restore Prx-III and
that cells overexpressing mitochondria-targeted Srx are re-
sistant to mitochondrial ROS-mediated cell death through the
restoration of the peroxidase activity of Prx-III (236). Com-
parative analyses in HeLa cells indicated that Prx-I is more
susceptible than Prx-II to hyperoxidation of the cysteine thiol
at their catalytic site to sulfonic acid, which is considered an
irreversible step. The mechanism underlying this differen-
tial susceptibility involved the acetylation of Prx-II in the
N-terminal domain, which prevents Prx-II from irreversible
hyperoxidation without altering its affinity for hydrogen per-
oxide (280).
A key mechanism to control the production of ROS is
through the transcriptional regulation of these enzymatic
strategies. For instance, a number of transcription factors, in-
cludingNrf1=2, whichworks in associationwith Keap1, along
with PGC1-a, and FoxO have been described to modulate
the expression of antioxidant enzymes such as MnSOD, Prx3,
Prx5, Trx2, and TR2, thus protecting against ROS overgen-
eration and oxidative stress in a number of conditions and cell
types (243, 290). Recently, a mutual dependence of FoxO3A
and PGC-1a in the induction of oxidative-stress genes was
described in endothelial cells (239). Expanding the role of
PGC-1a in mitochondrial biogenesis and protection against
oxidative stress, these data show a novel function of PGC-1a
acting as a partner for FoxO3 in the regulation of antioxidant
genes and hence ROS generation. Because FoxO3 also induces
proapoptotic proteins, further work is required to identify
additional coactivators that modulate FoxO target specificity.
In addition to these efficient enzymatic systems to scavenge
ROS, critical nonenzymatic antioxidants exist, some of which
collaborate with the enzymatic partners, such as GSH. This
critical antioxidant is a tripeptide (l-g-glutamyl-l-cysteinyl-
glycine), which owes its antioxidant function to the sulf-
hydryl group of cysteine (78, 159, 193). It is synthesized in the
cytosol of all cells from its constituents, amino acids, gluta-
mate, cysteine, glycine, and is then compartmentalized in var-
ious suborganelles (see later), where it plays a critical function
in the detoxification of hydrogen peroxide produced from su-
peroxide anion (96, 159). In addition to its redox-modulating
effects, GSH is a versatile antioxidant because of its function
as a cofactor for GSHPx and reductase (GR) in the so-called
GSH redox cycle. Given the relevance of GSH in the defense
against oxidative stress and in the susceptibility to different
stimuli, the regulation and role of GSH (in particular, nu-
clear and mitochondrial GSH) is further discussed later. Hy-
drophilic antioxidants such vitamin E play critical roles in
protecting lipid membranes from peroxidation by reacting
with lipid radicals produced in the lipid peroxidation reac-
tion, which removes the free radical intermediates and pre-
vents the oxidation reaction from continuing. The oxidized
a-tocopheroxyl radicals produced in this process may be
recycled back to the active reduced form through reduction
by other antioxidants, such as ascorbate, retinol, or ubiquinol
(301, 321). In most cases, the generation of ROS is controlled
by the availability and function of antioxidants. However,
when the former overwhelm the latter, oxidative stress
arises, compromising several cell functions by targeting and
modifying critical components, including proteins, lipids, and
DNA.
III. Oxidative Stress: More Than an Imbalance
Between Oxidants and Antioxidants
As originally defined in 1985, oxidative stress was an im-
balance between oxidants and antioxidants, in favor of the for-
mer (284). This implies that either the overgeneration of free
radicals and ROS and=or the limitation in the function of an-
tioxidants results in the net accumulation of ROS, which exert
deleterious effects in cell functions, ultimately contributing to
aging and major disease processes, including cardiovascular
disorders, pulmonary diseases, diabetes, neurodegeneration,
and liver diseases (32, 117, 289). This view has fostered the
idea that the downregulation of ROS by supplemented anti-
oxidants would be useful in the treatment of diseases, which
so far has not been proven effective. Large-scale interventional
studies in humans with antioxidants, based on the concept
that oxidative stress reflects an imbalance between proox-
idants and antioxidants, have been inconsistent in demon-
strating health benefits, particularly in cancer patients (182,
303). The idea that redox signaling may specifically involve
discrete pathways within cells suggests the possibility that
oxidative stress can actually occur without an overall imbal-
ance of prooxidants and antioxidants, and that the disruption
of redox-sensitive signaling pathways can lead to metabolic
and organ specificity in oxidative stress. In this regard, the
GSH=GSSG and cysteine=cystine redox potential have been
considered a useful estimation of the balance between oxi-
dative reactions and endogenous antioxidant defenses. How-
ever, studies in human plasma have shown that whereas GSH
concentration correlated with that of cysteine, no correlations
were found between GSSG and cystine (155). Moreover, the
redox-potential values (calculated by using the Nernst equa-
tion) showed that the plasma GSH=GSSG redox potential
(137 9mV) was more oxidized than the values reported
in cells (185 to 285mV), but less oxidized compared with
the redox potential values of cysteine=cystine (80 9mV).
Thus, the lack of equilibration regarding GSH=GSSG and
cysteine=cystine pools between plasma and tissues suggests
that these plasma redox levels do not appropriately reflect
the complexity of oxidative stress as an imbalance between
prooxidants and antioxidant systems (155). Thus, given these
considerations, the conception of oxidative stress has been
reoriented to reflect the disruption of thiol redox states, which
normally function in cell signaling and physiologic regula-
tion, without necessarily a net increase in reactive species.
Particularly in aging research, the concept of a beneficial
role for ROS in longevity has been provided in the so-called
hormesis theory. For instance, glucose restriction has been
shown to extend Caenorhabditis elegans longevity by stimu-
lating the mitochondrial ROS generation, which was pre-
vented by antioxidant pretreatment (275). A similar outcome
was reported in transgenic flies overexpressing Mn-SOD and
catalase, ectopically targeted to the mitochondrial matrix,
showing that the increased catabolism of superoxide anion
and hydrogen peroxide significantly reduced the life span of
flies (17). These findings indicate that the rate of mitochon-
drial ROS release is not simply and negatively related to the
life span and suggest that the increased formation of mito-
chondrial ROS may lead to a secondary increase in stress
defense, which ultimately results in reduced net stress levels
and extended life span. Hence, although ROS may play a
beneficial role by acting as signaling intermediates, their
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inappropriate generation linked to alterations in thiol redox
status may participate in the pathogenesis of diseases.
IV. Critical Balance Among Antioxidant Enzymes
to Prevent Hydrogen Peroxide Accumulation
In addition to the control of ROS generation by antioxi-
dants, a critical balance among antioxidant enzymes must
operate to avoid the overgeneration of oxidants such as hy-
drogen peroxide. This has been well documented in the case
of SOD and GSHPx, which modulate the conversion of su-
peroxide anion to molecular oxygen and water in a two-step
enzymatic process, involving first the dismutation of super-
oxide anion to hydrogen peroxide by SOD, followed by the
conversion of hydrogen peroxide to molecular oxygen and
water by GSHPx. Overabundance of SOD activity relative to
that of GSHPx activity may lead to a net increase in hydrogen
peroxide (Fig. 3), which can result in the harmful generation of
the hydroxyl radical by the Haber-Weiss=Fenton reactions.
Indeed, high levels of SOD have deleterious effects in cell
function and life span. For instance, patients with Down
syndrome carry three copies of Cu=ZnSOD gene in chromo-
some 21 and only two copies of GSHPx in chromosome 3 (75).
Fibroblasts derived from these patients display increased ac-
tivity of Cu=ZnSOD relative to GSHPx, resulting in increased
basal levels of hydrogen peroxide. Bacteria that overexpress
FeSOD or MnSOD show increased sensitivity to free-radical
generators such as paraquat (23). In Drosophila melanogaster,
overexpression of Cu=ZnSOD increases mortality during the
development of the mature insect (240). Culturedmammalian
cells overexpressing Cu=ZnSOD had increased lipid perox-
idation and hypersensitivity to oxidative stress, which could be
counterbalanced by increased catalase or GSHPx levels (2). The
low-molecular-weight SOD mimetic mangafodipir (manga-
nese dipyridoxyl diphosphate, MnDPDP) has been shown to
kill colon and liver tumor cells by a poorly understood mech-
anism, which contrasts with the effect observedwith two other
mimetics, manganese(III)tetrakis(4-benzoic acid) porphyrin
and copper(II)(3,5-diisopropylsalicylate)2 (177).
Although these studies suggest that dismutation of su-
peroxide anion is detrimental, the underlying mechanism
remains speculative, with the most-accepted interpretation
being that the increase in SOD levels leads to an increase in
steady-state concentration of its dismutation product, hy-
drogen peroxide. In line with this interpretation, we specifi-
cally assessed the role of mitochondrial GSH in the efficacy of
superoxide anion scavenging by an MnSOD mimetic in the
protection of rat liver mitochondria and cultured primary
hepatocytes against superoxide anion-induced dysfunction
and cell death (319). Selective mitochondrial GSH depletion
sensitized hepatocytes to antimycin A–mediated superoxide
anion generation and subsequent death in the presence of
MnTBAP compared with antimycin A alone. Together, these
findings indicate that the dismutation of superoxide anion
does not have a direct role in longevity and that the benefi-
cial effect of its conversion to hydrogen peroxide depends on
the fate of the resulting product, which is governed by the
GSH redox cycle. A clear example of this is the elegant study
of Giorgio et al. (116) in the characterization of cell and tis-
sues from p66Shc-null mice. P66Shc is a redox enzyme that
generates mitochondrial ROS, particularly hydrogen per-
oxide, as signaling molecules for apoptosis. For this func-
tion, p66Shc uses reducing equivalents of the mitochondrial
electron-transfer chain through the oxidation of cytochrome
c. Redox-defective mutants of p66Shc are unable to induce
mitochondrial hydrogen peroxide and to mediate mitochon-
drial apoptosis in vivo, resulting in extended life span (116).
Given the dual role of hydrogen peroxide in cell death and
proliferation, p66Shc-mediated hydrogen peroxide production
also is indispensable for cells to respond to the mitogenic ef-
fect of selected growth factors and the functional activation
of the Ras-p53–dependent checkpoint (116). Overall, a better
understanding of the regulation of redox signaling and the
balance of pathways modulating the fate of hydrogen per-
SOD GSHPx
GSH
H2O2
SOD GSHPx
GSH
SOD
GSHPx
GSH
SOD
GSHPx
GSH
FIG. 3. Critical balance among anti-
oxidant enzymes to prevent hydrogen
peroxide formation. Schematic represen-
tation indicating that the overabundance
of SOD relative to that of GSHPx may lead
to a net increase in hydrogen peroxide, as
shown in the case of fibroblasts from pa-
tients with Down syndrome. In addition
to this possibility and because GSHPx uses
GSH as a cofactor, its limitation may also
compromise the efficient elimination of
hydrogen peroxide, resulting in its accu-
mulation, which may lead to harmful ef-
fects.
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oxide may lead to novel opportunities for the treatment of
disease processes and aging.
Despite these findings regarding the deleterious effects
of increased hydrogen peroxide generation in aging, some
reports indicate that the overexpression of enzymes that
downregulate hydrogen peroxide promotes disease patho-
genesis. For instance, mice overexpressing GPx1 have been
shown to develop insulin resistance and obesity (209), sug-
gesting that increased GPx1 activity interferes with insulin
function by overquenching the intracellular ROS required for
insulin signaling. Moreover, as mentioned earlier, the SELECT
(Selenium and Vitamin E Cancer Prevention Trial) reports
showed inconsistent effects of antioxidants in cancer prophy-
laxis (182). In addition, the SELECT trial revealed a small
increase in diabetes incidence (22, 291). These findings on
longevity are consistent with the possibility that the extent of
ROS release is directly proportional to the rate of accumula-
tion of oxidatively damaged macromolecules, which in turn
govern the rate of aging under normal conditions. How-
ever, the adverse effects of enhanced scavenging of ROS and
hydrogen peroxide on cancer susceptibility and disease
progression suggest that a critical physiological threshold is
needed for proper cell function and signaling. At a more
speculative level, it remains open whether, in addition to se-
lenium and vitamin E, other antioxidants may have exerted
beneficial effects in cancer prophylaxis. Overall, these studies
imply that oxidative stress is far more complex than just
an imbalance between oxidants and antioxidants, and that
factors that regulate their source or compartmentalization or
both may influence the final outcome of antioxidant strategies
in disease pathogenesis.
V. Targets of Reactive Oxygen Species
A. Proteins
Cysteine is the most chemically reactive natural amino acid
found in cells because of the thiol group. Thiols are found in
proteins (PSH) and in low-molecular-mass metabolites such
as GSH. Two thiols can be oxidized to form a disulfide bond,
and disulfides are found mainly in proteins (PSSP), in GSSG,
or as mixed disulfides between protein and glutathione
(PSSG) (Fig. 4). In addition, thiols can be reversibly oxidized
by ROS to nitrosothiols or sulfenic acids, which are regener-
ated by Trx=TR. Disulfides are important for protein struc-
ture and folding, and formation of disulfide bonds can
regulate protein function (181). Furthermore, in addition to its
putative role in the regulation of the targeted protein, glu-
tathionylation (the formation of PSSG) has been suggested
as a mechanism for protection against irreversible protein
oxidation during oxidative stress (101).
The primary function of Trx is to maintain reduced PSH
pools in cells. The paradigm in this function is exemplified in
the case of Prx, whose primary role is the reduction of hy-
drogen peroxide, which results in oxidized Prx. Six isoforms
of mammalian Prx (Prx I to VI) are classified in three sub-
families: 2-Cys, atypical 2-Cys, and 1-Cys (256, 281). Prx I
through IV belong to the 2-Cys Prx subfamily and exist as
homodimers containing two conserved cysteine residues. In
the catalytic cycle of 2-Cys Prxs, the conserved NH2-terminal
Cys-SH is first oxidized by peroxides to cysteine sulfenic acid
(Cys-SOH), which then reacts with the conserved COOH-
terminal Cys-SH of the other subunit in the homodimer to
form a disulfide bond, which is specifically reduced by Trx
(Fig. 2). The resulting oxidized Trx is then regenerated by TR
by using NADPH as reducing equivalents (38). Because of the
slow conversion rate to a disulfide, the sulfenic intermediate
can be further oxidized to cysteine sulfinic acid (Cys-SO2H),
resulting in Prx inactivation, as this particular hyperoxidized
state is not reduced by Trx (38, 236, 253). Besides Prx, ROS
lead to the functional inactivation of Tyr and Ser=Thr phos-
phatases, including protein tyrosine phosphatase 1B, PTEN,
low-molecular-weight phosphotyrosine-protein phosphatase,
and Src homology phosphatase 2, through the formation of
intramolecular disulfide bridges or sulfenyl-amide bonds (34,
49, 50, 52, 213, 285, 336). ROS also result in the activation of
Tyr kinases by direct Cys oxidation (49). In this regard, recent
findings indicate that hypoxia-mediated mitochondrial ROS
stimulation results in c-Src activation through oxidation of the
critical Cys 487 (188). Moreover, redox regulation of Src has
been also involved in cell adhesion, spreading, anoikis resis-
tance, and renal hypertrophy (48–50).
Another mechanism involved in the modification of thiols
is through the addition of a NO moiety (S-nitrosylation)
or a glutathione moiety (S-glutathionylation), both of which
are produced by different reactions induced by nitric
oxide–related species (71, 204, 336). S-nitrosylation induced
by peroxynitrite formation shares some parallelism with
sulfenic acid formation, as it is reversible (252). S-thiolation,
the formation of a mixed disulfide between a protein thiol
and a low-molecular-mass thiol, also is a reversible process.
As glutathione is the most abundant intracellular low-
molecular-mass thiol and a key regulator of the redox state,
S-glutathionylation, the formation of a mixed disulfide with
glutathione, is considered the most important and abundant
thiolation mechanism in cells (39, 276). However, the forma-
tion of both modifications does not occur directly by addition
of the respective species nitric oxide ( NO) or glutathione
(GSH) to the protein cysteine thiol (204). A critical line of
defense against the glutathionylation of cysteine residues is
the availability of glutaredoxins (Grx), which are compart-
mentalized in different subcellular sites, where they play a
key role in restoring protein cysteine moieties to the sulf-
hydryl state (93).
S-SG
SH
S
S
SH
SH
SH
SNO
GSSG
ONOO-
ROS
GSSG
FIG. 4. Protein sulfhydryl fates. Cysteine is a chemically
reactive amino acid present in proteins. It can be a target of
ROS and oxidants. This scheme illustrates the major modi-
fications of protein sulfhydryl moieties undergoing disulfide
formation (which may then be restored by the Prx=Trx=TR
system, shown in Fig. 2), glutathionylation, or nitrosylation,
which may result in the alteration of protein function.
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B. Lipids
Phospholipids are predominant membrane components in
eukaryotic cells, where they distribute asymmetrically across
the bilayer. The most prominent phospholipids include
phosphatidylcholine, phosphatidylethanolamine, phosphati-
dylserine, phosphatidylinositol, and cardiolipin, which con-
sist of a hydrophilic head group with attached hydrophobic
acyl chains. Membrane phospholipids are highly sensitive to
oxidative modifications because oxygen and free radicals are
more soluble in the fluid lipid bilayer than in aqueous solu-
tion, and tend to concentrate in organic regions. A paradigm
of the significance of phospholipid oxidation in cell homeo-
stasis is cardiolipin, a mitochondrial phospholipid, whose
oxidation is a key event in the regulation of mitochondrial
apoptosis, as discussed in detail in Section C.2.b. The phos-
pholipid acyl chain normally varies from 14 to 22 carbons in
length, with a ratio between saturated and unsaturated fatty
acids of about 40:60, respectively (245). Thus, polyunsatu-
rated fatty acids (PUFAs) are essential components of phos-
pholipids and strongly affect their flexibility, selective
permeability, and fluidity. PUFAs are extremely sensitive to
oxidation, because the presence of a methylene group be-
tween two double bonds renders the fatty acid sensitive
to ROS-induced damage, becoming more susceptible as the
number of double bonds per fatty acid molecule increases.
Reactive free radicals can pull off hydrogen atoms from
PUFAs side chains, which are linked to a carbon in the fatty
acid backbone by a covalent bond (Fig. 5). In this reaction, the
carbon acquires an unpaired electron, becoming a free radi-
cal that combines with molecular oxygen dissolved in the
membrane. The resulting peroxy-radical is highly reactive and
more hydrophilic, contributing to its migration to the mem-
brane surface, where it can alter membrane dynamics, react
withmembrane proteins and,more important, further oxidize
adjacent PUFAs side chains. As a consequence, the process
of lipid peroxidation becomes amplified through this free-
radical chain reaction (35).
Lipid peroxidation generates hydroperoxides as well as
endoperoxides, which undergo fragmentation to produce
a broad range of reactive intermediates called reactive car-
bonyl species (RCS), three to nine carbons in length, includ-
ing highly reactive a,b-unsaturated hydroxyalkenals, such as
4-hydroxynonenal (4-HNE) and 4-hydroxyhexenal (4-HHE)
(Fig. 5). Oxidation of n-6 PUFAs (mainly linoleic and arachi-
donic acid) leads to the formation of 4-HNE (89), whereas
oxidation of n-3 PUFAs (docosahexaenoic acid, eicosapen-
taenoic acid, and linolenic acid) generates 4-HHE (308). 4-
HNE-protein adducts are frequently formed by the Michael
addition of 4-HNE to amino groups (Lys and His) or thiols
(Cys or GSH), followed by cyclization and hemi-acetal or
hemi-thioacetal formation, or by Schiff-base formation on
primary amines (Lys). These reactive aldehydes have a much
longer half-life (minutes to hours instead of microseconds to
nanoseconds) than most ROS and RNS radicals. In addition,
their noncharged structure allows them to migrate through
hydrophobic membranes and hydrophilic media (cytosol),
extending considerably the action area and increasing their
damaging effects on target sites located within or outside
membranes. In addition to the covalent modification of pro-
teins, 4-HNE can react with DNA and activate cellular stress-
response systems such as the transcription factors Nrf2 and
Tfam (250, 305). Besides hydroxyalkenals, RCS include alde-
hydes and dicarbonyls, such as acrolein, malondialdehyde
(MDA), glyoxal, and methylglyoxal (231). These aldehydes
react with proteins to form advanced lipid peroxidation end
products, altering protein functions and subsequent cellular
responses. MDA and acrolein are formed during lipid per-
oxidation and can bind to nucleophiles (251). MDA is one of
the most abundant aldehydes, resulting from peroxidation of
arachidonic, eicosapentaenoic, anddocosahexaenoic acid, and
has been shown to alter protein functions (89). For instance,
on reaction with Lys residues resulting in the formation of
Schiff bases, MDA modulates low-density lipoproteins (287).
Acrolein is a strong electrophile with high reactivity toward
Cys, His, and Lys nucleophile residues (304). Another type of
reactive lipid peroxidation end products is a-oxoaldehydes
(methylglyoxal and glyoxal), which react with Lys and argi-
nine residues (231).
Because of the reactivity of the by-products of lipid per-
oxidation, adducts or cross-linkings on proteins are formed,
which progressively lead to impaired protein function, caus-
ing alterations in signal transduction that affect cell dys-
function, inflammatory response, and cell death (248). As a
consequence, oxidative lipid damage is considered an im-
portant contributing factor in aging, atherosclerosis, alcoholic
liver disease, and diabetes (31, 51, 245).
These deleterious effects are modulated by the presence
of cellular metabolizing systems, in particular GSH, which
plays a major role in the protection against lipid peroxidation.
Although GSH can react spontaneously with 4-HNE through
a Michael addition, the reaction catalyzed by GST is kineti-
cally accelerated, resulting in the formation of a 4-HNE-GSH
conjugate with the subsequent consumption of net GSH
equivalents. GSTA4-4 is the main GST responsible for the
metabolism of most long-chain a,b-unsaturated aldehydes,
Proteins
DNA
Phospholipids
COVALENT ADDUCTS
Lipid Lipid-OOH
Gpx
GSH              GSSG
OH.
MDA
4-HNE
GLYOXAL
4-HHEFragmentation
Cellular
damage
FIG. 5. Lipid peroxidation and forma-
tion of reactive aldehydes. Free radicals,
such as the hydroxyl radical, can react
with lipids to generate hydroperoxides as
well as endoperoxides. These species may
undergo fragmentation to produce reactive
intermediates, such as 4-hydroxynonenal
(4-HNE), 4-hydroxyhexenal (4-HHE), ma-
lodialdehyde (MDA), and glyoxal, able
to generate irreversibly covalent adducts
with proteins, DNA, and phospholipids,
leading to cell death.
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although other GSTs may be involved, in particular, GSTA3
(8). GSTA4 catalyzes the glutathionylation of a,b-unsaturated
aldehydes to produce a poorly reactive conjugation product
that is transported out of the cell. In addition, GSH reduces
hydroperoxide formation during lipid peroxidation through
GSHPx, thus limiting 4-HNE generation (147). This is a critical
mechanism for cell protection, as 4-HNE has been described
to impair mitochondrial function due to oxidative stress by
limiting mitochondrial GSH, which could initiate a vicious
circle between 4-HNE and mitochondrial dysfunction (179,
255). In addition, although it has been shown that mildly
cross-linked HNE-modified proteins are preferentially de-
graded by the proteasome, extensive modifications by cross-
linking aldehyde lead to the formation of protein aggregates
that eventually inhibit the proteasome, contributing to cellu-
lar damage (122). In this regard, NF-kB activation has been
shown to be inhibited by 4-HNE and acrolein, either through
direct inhibition of the degradation of IkB by the proteasome
or by specifically preventing the phosphorylation of IkB
(242).
C. DNA
Cellular DNA is also subject to oxidative damage on ex-
posure to a wide range of environmental genotoxins, anti-
cancer drugs, or ROS, being particularly relevant in the case
of mitochondrial DNA (10). Compared with the nuclear ge-
nome, the mitochondrial genome is highly vulnerable to
oxidative stress, given its open circular structure, lack of his-
tone protection, and proximity to the mitochondrial electron-
transport chain, the main source of superoxide radical and
hydrogen peroxide (225, 329). Oxidative mitochondrial DNA
modifications include damage to purine andpyrimidine bases,
sugar-phosphates, as well as single- or double-strand breaks.
In this regard, the formation of 7,8-dihydro-8-oxoguanine
(8oxodG) is commonly used as ameasure of oxidative damage
to DNA (128, 266). Consistent with this, mitochondrial GSSG
has been shown to correlate with age-associated oxidative
damage to mitochondrial DNA (76). Oxidative base damage
does not involve direct superoxide anion or hydrogen perox-
ide attack on DNA but arises by the action of hydroxyl radical
generated through reactions of hydrogen peroxide with metal
ions (iron or copper) in close proximity to DNA. Moreover,
superoxide anion and hydrogen peroxide (derived from qui-
none redox cycling) can induce DNA strand breaks reflective
of endonuclease activation (128). Although lacking important
nuclear nucleotide excision repair, mitochondria are endowed
with an efficient base-excision repair system for the repair of
oxidized bases (162, 258). Repair begins by the mitochondrial
DNA glycosylase that recognizes and removes the damaged
base, followed by the apurinic endonuclease that generates an
apurinic=apyrimidinic site. Enhanced mitochondrial DNA
repair induced by menadione has been associated with cell
survival by targeting 8-oxodG glycosylase (OGG1) to the mi-
tochondria (84). An adaptive response to increasing ROS
concentrations has been linked to elevated apurinic endonu-
clease 1 levels, increased DNA repair rate, and attenuated
oxidative mitochondrial DNA damage. In addition, a key
feature of mitochondrial DNA is its organization as protein–
DNA macrocomplexes, called nucleoids (113). Average nu-
cleoids contain two to eight mitochondrial DNA molecules,
which are organized by the histone-like mitochondrial tran-
scription factor A. Recent evidence showed the presence of
antioxidant enzymes, MnSOD and GSHPx1, as integral com-
ponents of nucleoids tomaintainmitochondrial DNA integrity
(162). Thus, given the role of mitochondria as a source of ROS
formation and in cell-death regulation, the preservation of
intact mitochondrial DNA stability by mitochondrial antioxi-
dants may be essential in the control of apoptosis and cell-
death susceptibility during oxidative stress.
D. Signaling pathways
By targeting protein thiols, ROS generation can alter sig-
naling pathways (e.g., kinases and phosphatases cascades,
and transcription factors), which may have profound effects
in multiple cell functions, including proliferation, differenti-
ation, or cell death. ROS may ultimately commit hepatocytes
for apoptotic=necrotic cell death by activating oxidant-
induced hepatocyte apoptosis or by inhibiting cell-survival
signaling cascades. The mitogen-activated protein kinases
(MAPKs) constitute a family of serine=threonine kinases that
includes extracellular signal-regulated kinase 1=2 (ERK1=2),
c-Jun N-terminal kinase ( JNK), and p38 MAPK (69, 70). These
enzymes are positively regulated by upstream kinases and
inactivated by phosphatases. Activated MAPKs transduce a
multitude of extracellular stimuli by phosphorylating and
activating downstream transcription factors such as c-Jun and
activating transcription factor-2 (ATF-2). Importantly, the role
of this cascade in oxidant-dependent hepatocyte cell death
depends on the intensity or duration or both of the stimuli. For
instance, nontoxic concentrations of menadione induced low
levels of transient ERK1=2 and JNK activation, whereas toxic
concentrations of menadione led to markedly increased and
prolonged activation of ERK1=2 and JNK. Although ERK1=2s
are critical for hepatocyte resistance to superoxide anion
generation by menadione, the sustained activation of JNK
accounted for hepatocyte death, overcoming the effects of
ERK1=2. In addition, ROS-mediated inactivation of MAPK
phosphatase has been shown to contribute to hepatocyte
death after TNF exposure (158). Thus, ROS can target different
redox-sensitive pathways, whose interplay and final outcome
in hepatocyte survival=death depends on the degree or du-
ration or both of the activation=inactivation of these cascades,
in particular, the relative level of activation of NF-kB, ERK1=2,
or JNK. Because the underlying mechanism responsible for
the modulation of cell-signaling cascades by ROS involves the
redox status of protein cysteine thiols, antioxidant strategies
also can control signaling pathways. In addition to Trx=TR=
Prx, GSH and related enzymes have been shown to preserve
PSH status and activity. For instance, GSH S-transferase
(GST) Pimonomer has been reported to regulate the activation
of the redox-sensitive kinase JNK (1). GSSG formation pro-
motes the oligomerization of GSH S-transferase Pi, liberat-
ing active JNK, which regulates cell death. Similarly, ASK1,
a MAPK kinase upstream of JNK and p38, is inhibited by
reduced Trx. GSSG formation promotes oxidation of Trx,
liberating active ASK1 (265). Moreover, GST mu1 (GST M1)
protected primary hepatocytes against TGF-b1–induced
apoptosis by blocking ASK1, a MAP kinase kinase kinase
(MAPKKK) ubiquitously expressed, which mediates the
activation of downstream targets, including JNK (c-Jun N-
terminal kinase) and p38 MAP kinase by inflammatory
cytokines (114).
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VI. Hepatic GSH and Redox-Dependent
Cell-Death Regulation
A. GSH synthesis and regulation
Among the armamentarium of antioxidants, the tripeptide
GSH plays a central role, as it is the most abundant intra-
cellular thiol, reaching millimolar concentrations in most cell
types, especially in the liver. GSH is involved in many cellular
functions, including antioxidant defense, by scavenging ROS
in a chemical reaction driven by the potential of the redox
environment toward equilibrium. In addition, GSH acts as a
coenzyme of detoxification enzymes like GSH peroxidases
andGSH-S-transferases (159, 193). GSHplays an essential role
in maintaining the intracellular redox environment that is
critical for the function of various cellular proteins. Although
several reducing couples, such as GSH=GSSG, NADPþ=
NADPH, and Trx=TR, contribute to maintain the intracellular
reducing environment, the GSH concentration is considerably
greater than that of other couples and is therefore a deter-
mining factor of the redox potential, in which both GSH
concentration and the molar ratio of GSH=GSSG contribute
according to the Nernst equation
DE¼E0 (RT=nF)lnQ
where Q denotes log([GSH]2)=[GSSG]. However, com-
pared with GSH=GSSG ratio (about 100), which is maintained
mainly by constant reduction of GSSG from NADPH reduc-
ing equivalents through catalysis of GR, the absolute GSH
concentration may be a more-sensitive factor in redox po-
tential, because of the square of the GSH concentration,
according to the Nernst equation.
Hepatic GSH is maintained at a relatively constant con-
centration through GSH synthesis and turnover.De novoGSH
synthesis occurs exclusively in the cytosolic compartment in
two sequential ATP-dependent steps that are catalyzed by
g-glutamyl cysteine synthase (also called glutamate cysteine
ligase, GCL) andGSH synthetase (212) (Fig. 6). GCL-catalyzed
formation of g-glutamylcysteine is the first and rate-limiting
reaction in GSH synthesis, and it is feedback inhibited byGSH
itself, a mechanism that is central in the regulation of cellular
GSH concentrations (121). Cysteine is a rate-limiting substrate
for de novo GSH synthesis and is derived from extracellu-
lar GSH breakdown by g-glutamyl transferase (GGT) and=or
from methionine-to-cysteine conversion in the transsulfura-
tion pathway, in which the thiol of cysteine derives from
methionine, with serine contributing to its carbon backbone.
A key intermediate involved in this process is the synthesis of
S-adenosyl-l-methionine (SAM) from methionine (193, 205).
Thus, in addition to its role in methylation reactions in mul-
tiple cell types, the function of SAM as a GSH precursor is
more restrictive, being particularly relevant in the mainte-
nance of hepatic GSH homeostasis (95, 109, 205). Whereas
the cystathionine pathway is characteristic in liver cells, the
cleavage of circulating GSH takes place at the external plas-
ma-membrane surface of various epithelial cells, such as
kidney, pancreas, bile duct, and small intestine. In the GGT-
catalyzed reaction, the g-glutamyl moiety is transferred from
GSH or GSH conjugates to acceptors like amino acids, di-
peptides, or GSH itself, whereas cysteinylglycine is cleaved
by membrane-bound dipeptidases. The resultant constituent
amino acids and g-glutamyl products are taken up into cells
for de novo GSH synthesis. Thus, the GGT reaction is part of
the g-glutamyl cycle in intracellular GSH synthesis and GSH
homeostasis (212).
In addition to the availability of cysteine, and because GCL
catalyzes the rate-limiting step of GSH synthesis, the regula-
tion of GCL constitutes a major step in the homeostasis of
GSH. In general, GCL gene expression is upregulated under
conditions in which increased cellular defense is neces-
sary, and many agents have been described to elevate its
expression, including xenobiotics (e.g., 5,10-dihydroindeno
-[1,2-b]indole, tert-butyl hydroquinone), metals (e.g., zinc),
Michael reaction acceptors (e.g., diethyl maleate), and lipid
peroxidation products, such as HNE and 15-deoxy-D12,14-
prostaglandin J2 (15d-PGJ2) (25, 127, 333). Selenium deficiency
also has been shown to upregulate the expression of the
catalytic GCL subunit, resulting in the downregulation of
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FIG. 6. Glutathione synthe-
sis and compartmentation.
Glutathione (GSH) is synthe-
sized in the cytosol by an
ATP-dependent two-step pro-
cess catalyzed by g-glutamyl
cysteine synthase (g-GCS) and
GSH synthetase (GS). Once
synthesized, GSH is distrib-
uted to other organelles, such
as the nucleus, the endoplas-
mic reticulum (ER), and the
mitochondria,whichconstitute
distinct redox pools in terms
of GSH=GSSG distribution. To
reach the mitochondria, GSH
requires a carrier-mediated
transport to cross the mito-
chondrial inner membrane.
The dicarboxylate carrier (DIC)
and the 2-oxoglutarate carrier
(2OG) have been shown to
function as GSH transporters.
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plasma homocysteine and in the increase of plasma GSH
(307). ConsensusNF-kB, Sp-1, AP-1, activator protein-2 (AP-2),
metal response, and antioxidant response (ARE)=electrophile-
responsive elements have been identified in the humanGCLC
promoter. Previous studies have identified a proximal AP-1
element (263 to269) to be critical in mediating the effect of
oxidative stress in the transcriptional induction of human
GCLC (223). A critical distal ARE element (ARE4), located
3.1 kb upstream of the transcriptional start site, has been de-
scribed, which mediated constitutive and xenobiotic induc-
ible expression in HepG2 cells (226). In this response, the
transcription factor Nrf2 plays an essential role by forming
complexes with other Jun or Maf proteins, which bind to
ARE4 in response to b-naphthoflavone, tert-butyl hydroqui-
none, or hydrogen peroxide (82, 324). Nrf1 and Nrf2 are
members of the basic leucine-zipper proteins that can trans-
activate ARE (151, 175), and these transcription factors
have been shown to regulate rat GCLC promoter by modu-
lating the expression of key AP-1 and NF-kB family members
(193).
B. GSH compartmentation
1. Endoplasmic reticulum. Once synthesized in the cyto-
sol, GSH is compartmentalized in discrete organelles such as
ER, nuclei, and mitochondria, where it constitutes distinct
redox pools in terms of the GSH=GSSG distribution, redox
potential, and control of cellular activities (Fig. 6). The ER pool
typically exhibits a total GSH (GSHþGSSG) concentration
similar to that found in the cytosolic compartment (2– 10mM).
Based on previous findings (144), a feature of the ER redox
environment is that GSH is in a predominant oxidized state,
which is thought to favor disulfide bond formation and
proper folding of nascent proteins in a process catalyzed by
protein disulfide isomerase, in which oxidation of catalytic
thiols is essential for proper enzyme activity. Despite its rel-
evance to ER physiology, only a few studies have reported the
status of GSH in the ER. An initial study using a tetrapeptide
probe in a hybridoma cell line reported a GSH=GSSG ratio
that varied from 1.5:1 to 3.3:1 (144), thus fostering the notion
that a significant proportion of GSH is in the oxidized form.
Another approach with monobromobimane estimated an ER
GSH=GSSG status of 3:1, confirming the relative oxidizing
GSH redox in the ER compared with the cytosol. Because of
this oxidation state, the accurate quantification of the GSH
redox status in ER is difficult and is subject to artifacts. In this
regard, by using iodoacetic acid to preserve the GSH redox
state and to avoid ex vivo oxidation during sample prepara-
tion, GSH concentration in rat liver microsomes was reported
to be*4– 6mM, which is in the range of previous estimations
(15). Intriguingly, although the use of iodoacetic acid to
minimize the extensive oxidation during microsomal isola-
tion estimated a GSH=GSSG ratio somewhat higher (5:1) than
previously reported (15, 144), this approach did not affect the
extent of glutathionylation of ER-resident proteins, which
represented a minor fraction of the total GSH found in the ER
(83), as opposed to previous reports (15). Although further
work in understanding the homeostasis of GSH in the ER is
needed, these new insights suggest that mixed disulfides be-
tween GSH and ER proteins is a rate-limiting step in enzyme-
catalyzed protein folding. Furthermore, it could be speculated
that glutathionylation in the ER is a highly regulated process
kept to a minimum to limit protein transit time through the
secretory pathway to regulate protein maturation and deg-
radation in the ER. Moreover, the reductase activity of dis-
ulfide isomerase has been shown to be dependent on a
reduced GSH status (83). These features imply that the role of
GSH in the ER is to maintain oxidoreductase catalytic func-
tion and the appropriate redox environment to control ER-
generated ROS and redox state, which otherwise may disrupt
ER function, resulting in the activation of the unfolding pro-
tein response and subsequent cell death (40, 153).
2. Nuclei. The nuclei exhibit an independent GSH pool,
which plays an important role in the protection against
oxidant- and ionizing radiation–induced DNA damage, as
well as in the maintenance of nuclear proteins in an adequate
redox status required for gene transcription (65, 225, 244). In
addition, GSH functions as a hydrogen donor in ribonucle-
otide reductase–catalyzed reduction of ribonucleotides to
deoxyribonucleotides, thus playing a critical role in DNA
synthesis (142). Recent studies showed that the nuclear GSH
pool is not in equilibrium with cytosolic GSH, with higher
nuclear-to-cytosolic GSH levels reported in different cell
types, including rat hepatocytes and developing neurons
(18, 296). The trafficking of nuclear GSH is a dynamic pro-
cess, which correlates with cell-cycle progression. A higher
nuclear-to cytosolic GSH gradient has been associated with
proliferative states, whereas an even distribution between
the two compartments predominates in confluent cells (202,
244). However, because the nuclear membrane breaks down
during cell division, it is conceivable that the homogeneous
distribution of GSH between nuclei and cytosol after cell
proliferation may reflect the loss of compartmentation.
Nevertheless, the mechanisms underlying the trafficking
and dynamics of nuclear GSH distribution are poorly un-
derstood, although a passive diffusion of GSH from the cy-
tosol to the nuclei via nuclear pores has been suggested as the
responsible mechanism (Fig. 6) (139). Intriguingly, a novel
role for Bcl-2 in the maintenance of high nuclear GSH levels
has been described (318). Although the mechanism under-
lying this observation remains to be fully established, an-
other related observation indicated the ability of GSH to bind
to the Bcl-2 homology-3 domain groove in mitochondria
(342). Whether this binding described in mitochondria oc-
curs in nuclei remains to be further investigated.
3. Mitochondria. Mitochondria are the main consumers
of molecular oxygen in the cell, which is used as a transducing
device to provide the energy required for ATP synthesis in the
oxidative phosphorylation. One of the collateral effects of this
constant oxygen consumption is the leakiness of electrons to
molecular oxygen, resulting in the formation of ROS (Fig. 1).
As indicated earlier, mitochondria are endowed with a wide
range of antioxidant strategies, most notably GSH, which
represents a metabolically separated pool with respect to the
cytosol in terms of synthesis rate and turnover, first described
in the 1970s (154). As mitochondria do not contain catalase,
the GSH redox cycle is the main defense to avoid hydro-
gen peroxide accumulation. Mitochondrial GSH (mGSH) is
predominantly in the reduced form and represents a minor
fraction of the total GSH pool (10–15%) (Fig. 6). Considering
the volume of the mitochondrial matrix, the concentration of
mGSH may be similar to that of cytosol (*10mM) (111, 120).
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Because the mGSH concentration is high, moderate depletion
of mGSH would not be expected to affect negatively the dis-
posal of hydrogen peroxide by GSHPx or the mitochondrial
function. However, the depletion of mGSH below a critical
level can compromise the adequate reduction of hydrogen
peroxide, particularly in conditions of stimulated ROS gen-
eration from the mitochondrial electron-transport chain.
Thus, under complex III inhibition by antimycin A, increased
hydrogen peroxide generation was observed only when GSH
was depleted to 2–3 nmol=mg protein (110), which corre-
sponds to the range of the Km of GSHPx for GSH (183). De-
pletion of mGSH below 40% leads to stimulated hydrogen
peroxide generation from complex I (130). Furthermore, GSH
contributes to the reduction of organic hydroperoxides, in-
cluding products of lipid peroxidation, through GST and
GSHPx (21, 44). Despite the high GSH concentration existing
inmitochondrial matrix, de novoGSH synthesis does not occur
in this organelle, andmitochondrial GSH arises by the activity
of specific carriers, the 2-oxoglutarate carrier (2-OG) and the
dicarboxylate carrier (DIC) that have been partially charac-
terized in kidney and liver (45, 46, 61). These antiport carriers
have been shown to import cytosolic GSH into mitochondria
against an electrochemical gradient in the exchange of matrix
dicarboxylates (201). Whether these carriers also participate
in the efflux of mGSH in exchange for cytosolic GSH is un-
known. Remarkably, a recent study with an immortalized
human colonic epithelial cell line reported that butylmalonate
and phenylsuccinate, inhibitors of DIC and 2-OG, respec-
tively, increased rather than decreased mGSH levels without
changing the cytosolic GSH pool, suggesting that these car-
riers exchanged mGSH for cytosolic GSH (54). However,
whether these observations are specific for the particular cell
line used remains to be established. Furthermore, recent evi-
dence in cultured neuronal cells implied a role for the anti-
apoptotic Bcl-2 member in the modulation of mGSH pool at
mitochondrial membrane sites (342). As with the nuclear
trafficking of GSH, the role of Bcl-2 in the trafficking of GSH
into mitochondria remains to be fully understood. Moreover,
a role for UCP2 in the transport of mitochondrial GSH has
been described in neurons, suggesting that the transport of
protons back into the matrix by UCP2 may favor the move-
ment of GSH (73). Unlike 2-OG and DIC carriers, the evidence
for these alternative carriers in the transport of mitochondrial
GSH in hepatic liver mitochondria remains to be established.
A key feature of the transport of GSH through 2-OG is its strict
dependence on appropriate membrane dynamics (96), which
is determined by fatty acid composition and the cholesterol=
phospholipid molar ratio (61, 189). Reduction of appropriate
membrane fluidity impairs this transport system, resulting
in mGSH depletion. This selective pool of GSH has been
shown to play a key role in controlling cell susceptibility
to oxidative stress, Ca2þ overload, TNF=Fas, and hypoxia
(7, 188, 190, 192, 197, 198), and its depletion has been
shown to contribute to a number of pathologies (96, 104,
169). Interestingly, the hepatocellular susceptibility to TNF
induced by mGSH depletion was observed despite unim-
paired GSHPx, Trx2, and PrxIII, thus highlighting the rele-
vance of this antioxidant in cell protection under oxidative
stress. By regulating the mitochondrial ROS generation,
mGSH was recently shown to play a key role in the preser-
vation of the reduced cardiolipin status (198), which regu-
lates cell-death pathways, as described later.
C. Role of GSH in cell death
1. Mechanisms of cell death. Among the various
recognized forms of cell death that include necrosis and au-
tophagy, apoptosis is evolutionarily conserved, highly orga-
nized, and characterized by distinctive nuclear changes,
chromatin shrinkage, DNA fragmentation, membrane bleb-
bing, and the formation of apoptotic bodies that contain
components of the dying cell. Since its rediscovery in the early
1970s (161), it has become an intense field of research because
of its involvement in the development of pathologic states
characterized by either the decreased (e.g, cancer) or increased
(e.g., steatohepatitis) incidence of apoptosis (98, 119, 196). The
morphologic features of apoptosis are generated during the
activation of specific cellular cysteine proteases (caspases)
(268) that can occur through two main pathways: death
receptor– (also called extrinsic) or mitochondria- (also called
intrinsic) mediated pathways.
The extrinsic death-receptor–mediated pathway is triggered
by extrinsic signals, such as components of the tumor necrosis
factor family (TNF), like TNF, Fas=CD95 ligand, or TRAIL,
which bind to death receptors on the plasmamembrane. At the
level of the activated receptor, proapoptotic proteins interact
through their death domains or death-effector domains, re-
sulting in the formation of the death-inducing signaling com-
plex (DISC) (214, 227). Initiator caspases, such as caspase-8 or
caspase-10, are recruited to the DISC, and on activation, they
trigger a caspase cascade that determines the downstream ac-
tivation of executioner caspases-3 and 7, followed by apo-
ptosis-induced cellular demise. In certain cell types, type II
cells, such as hepatocytes, the activation of caspase-8 by TNF is
weak and, therefore, insufficient to complete cell apoptosis
(270). In type II cells, the cleavage of the proapoptotic protein
Bid by active caspase-8 engages the mitochondrial apoptotic
cascade, establishing a cross-talk between the death-receptor
and mitochondrial pathways in apoptotic signaling. In addi-
tion to the TNF receptor 1 internalization, another critical step
in TNF signaling involves endosomal trafficking and activation
of acidic signaling components, including sphingomyelinases
(224, 273) (see later).
The intrinsic mitochondrial apoptotic pathway involves
the release of proapoptotic proteins from mitochondria to
the cytosol. Different apoptotic stimuli, such as ROS=RNS
and mitochondrial DNA damage, can mediate mitochondrial
outer membrane (MOM) permeabilization and the release of
mitochondrial proapoptotic proteins, like cytochrome c, AIF,
or second mitochondria-derived activator of caspases=direct
IAP-binding protein with low pI (Smac=Diablo) (98, 119,
316). Within the cytosol, these apoptogenic proteins trigger
caspase-dependent or caspase-independent signaling events.
For example, cytochrome c binds to the apoptotic protease-
activating factor-1 (Apaf-1) and forms the apoptosome to
which procaspase-9 is recruited. The ATP-dependent cleav-
age of procaspase-9 signals downstream activation of effector
caspases, such as caspase-3 and 6=7. Additionally, Smac=
Diablo, which antagonizes inhibitors of caspases, enhances
caspase activation. Interestingly, through mitochondria-
to-nuclear translocation, AIF participates in caspase-
independent mitochondria-mediated apoptosis, in which it
induces chromatin condensation and DNA fragmentation
(297). Because MOM constitutes a physical barrier that pre-
vents the release of these apoptotic proteins, the breakage of
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this membrane controls cell death. At least two mechanisms
underlying MOM permeabilization have been suggested,
which differentiate depending on whether the mitochondrial
inner membrane (MIM) permeabilization occurs, involving
either a primary role of the mitochondrial permeability tran-
sition (MPT) or the Bcl-2 network (13, 171). In the former, the
usually impermeable MIM prevents unrestrained influx of
low-molecular-weight solutes into the mitochondria. The
MPT features mitochondrial swelling, uncoupling, and MIM
permeabilization to small solutes, which results in a colloidal
osmotic pressure that leads primarily to massive swelling of
the mitochondrial matrix (171). As a consequence of MPT, the
MOM ruptures, and cytochrome c and other mitochondrial
intermembrane space proteins are released into the cytosol.
MTP is most likely assembled at the contact sites formed by
the physical interaction of MOM and MIM. Although the
actual components of the MTP remain to be fully described,
evidence indicates a role for VDAC, ANT, and cyclophylin D
in this process. However, the role of VDAC in apoptosis is
uncertain (9), whereas cyclophilin D has been shown to be a
key factor in necrosis induced by ischemia=reperfusion (229).
The other model proposes that Bcl-2 family proteins, par-
ticularly BH1-3 members such as Bax=Bak, control MOM
permeabilization. In this regard, Bax oligomerization is con-
sidered a critical regulatory point in cell death by the for-
mation of pores in MOM (119, 171). However, attempts to
visualize these oligomers have shown that large clusters of
Bax are localized near, but not on, the MOM. An alternative
model suggests that the insertion of activated, oligomerized
Bax or Bak or both into the MOM creates a positive curvature
stress on the membrane, leading to supramolecular pores that
include lipids (lipidic pores) in the MOM (14, 174). Clearly,
understanding the mechanisms underlying MOM permeabi-
lizationmay provide novel strategies to regulate cytochrome c
release and hence apoptosis.
2. Regulation by GSH
a. Regulation of the extrinsic pathway. Critical signal-
transduction and transcriptional pathways are activated by
redox stress, which contributes to many forms of liver injury
and diseases. Because GSH modulates these redox pathways,
the role of GSH in hepatocellular death has been critically ex-
amined in response to TNF and Fas, two ligands of the TNF-
receptor family with relevance in liver diseases (100, 196). An
important aspect in the signaling of TNF on binding to its re-
ceptor is the stimulation of both survival and death signals,
which are exemplified by the formation of two sequential sig-
naling complexes, the balance of which determines the ultimate
fate of cells (214, 227). In brief, the rapidly forming complex I is
assembled on the receptor’s cytoplasmic tail and consists of the
adaptor TRADD, the protein kinase RIP1, and the signal
transducer TRAF2. This complex signals inflammation and
survival through IkB kinase (IKK)-dependent activation of
transcription factor NF-kB. Subsequently, complex I dissociates
from the receptor, and TRADD together with RIP1 associate
with the adaptor protein FADD and procaspase-8 to form
complex II. Activation of caspase-8 can lead to the proteolytic
activation of executioner caspase-3, which contributes to the
apoptotic demise of the target cell. As mentioned earlier, in
hepatocytes, the activation of caspase-3 requires the participa-
tion ofmitochondria and the apoptosome assembly through the
cleavage of Bid by the active caspase-8, resulting in the forma-
tion of a truncated fragment that elicits the mitochondrial
membrane permeabilization requiring the participation of Bax=
Bak (270).
Through maintenance of protein sulfhydryls in the appro-
priate redox state, GSH can regulate the activity of caspases
and NF-kB, thus modulating the death=survival balance and
the susceptibility to TNF (55, 85, 97). The effect of GSH de-
pletion on DISC and caspase-8 activation by death ligands is
controversial, with the outcome dependent on the specific cell
type used (138). Thus, mouse hepatocytes are rendered sus-
ceptible to TNF-induced cell death by GSH depletion in the
cytosol by impairing TNF-mediated NF-kB transactivation
and the subsequent activation of survival pathways by IkB
kinase–dependent and –independent mechanisms (191, 206,
228). Moreover, severe GSH depletion induced necrosis of
primary mouse hepatocytes, whereas the addition of TNF
sensitized to apoptosis, involving increased caspase activity
and cytochrome c release. Thus, the extent and site of GSH
depletion (cytosol or mitochondria or both) can determine the
fate of hepatocytes in response to TNF and the mode of death
(apoptosis versus necrosis). Moreover, redox regulation of NF-
kB constitutes a primary mechanism determining the sus-
ceptibility of hepatocytes to TNF, primarily by modulating
the expression of survival genes, which control caspase acti-
vation. However, in addition to this function, NF-kB also is
known to modulate the generation of ROS from mitochon-
dria, resulting in the subsequent sustained activation of stress
kinases such as JNK (158, 315). In this regard, NF-kB con-
tributes to the transcriptional upregulation ofMn-SOD aswell
as to the induction of the ferritin heavy chain, which modu-
late TNF-mediated ROS generation (29, 249). Interestingly, a
novel mechanism of noncanonic NF-kB activation through a
multistep pathway was described recently, involving a Bcl-3=
p50 complex in U937 cells after GSH depletion by BSO (68).
This process requires two steps: an early phase accompanied
by substantial GSH depletion produces a cytosolic prepara-
tive complex consisting of p50 and its interactor Bcl-3 linked
by interprotein disulfide bridges. In a late phase that coincides
with ROS production, the complex is targeted to the nucleus,
resulting in the transactivation of Bcl-2 and resistance to
BSO-mediated apoptosis. Overall, these data suggest that the
outcome of GSH depletion on NF-kB may be dependent on
the type of cell=stimuli used, as well as the pathway of NF-kB
activation (canonic versus noncanonic). Another key aspect in
this differential outcome may relate to the compartmentation
of GSH depletion (cytosol versus nuclei) and the consequent
redox regulation of Trx, particularly in the nuclei, which
promotes the reduced state of NF-kB (208). Cross-talk be-
tween caspase activation and redox regulation of Grx-1 in
response to Fas was recently described in type I cells (murine
alveolar epithelial cells, fibroblasts, and CD4þ T lymphocytes)
(3). Stimulation of Fas ligand induced S-glutathionylation of
Fas at cysteine 294 due to caspase-dependent Grx1 degrada-
tion, which amplified subsequent caspase activation and ap-
optosis. Although this process defines a novel redox-based
mechanism to propagate Fas-dependent apoptosis, it remains
to be established whether this mechanism occurs in hepato-
cytes. Consistent with this possibility, it is known that Fas
stimulates ROS generation in hepatocytes, which favors
the formation of its reduced form GSSG and hence the
S-glutathionylation of target proteins, such as Fas.
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b. Regulation of the intrinsic pathway. In addition to the
critical role of the MOM permeabilization in cytochrome c
release and subsequent apoptosome activation and cell death,
cytochrome c mobilization from the mitochondrial inter-
membrane space constitutes a central mechanism in cell-death
regulation. It has been proposed that during apoptosis, cy-
tochrome c detaches from the MIM by dissociating from
the membrane phospholipid cardiolipin (117). A significant
proportion of the cytochrome c in the mitochondria seems to
be associated with cardiolipin, involving two major mecha-
nisms. At physiologic pH, cytochrome c has þ8 net charges,
establishing an electrostatic bondwith the anionic cardiolipin.
In addition, cytochrome c has a hydrophobic channel through
which one of the four acyl chains of cardiolipin inserts. The
other chains of cardiolipin remain in the membrane, anchor-
ing cytochrome c to the MIM (157). One of the mechanisms
involved in cytochrome c detachment from MIM includes
cardiolipin oxidation, because oxidized cardiolipin has a
much lower affinity for cytochrome c than the unoxidized
form (170, 198). Cardiolipin oxidation occurs by different
mechanisms, including the formation of a cardiolipin–
cytochrome c complex with a stimulated peroxidase activity
(117, 156). Furthermore, mGSH has been shown to control the
formation of peroxidized cardiolipin during TNF-mediated
hepatocellular cell death by regulating ROS generation (198).
In addition, by using liposomes mimicking the composition
of MOM entrapping fluorescent dextrans, it was observed
that the incorporation of peroxidized cardiolipin in the bi-
layer enhanced the pore-forming activity of active Bax by
restructuring the lipid bilayer through a mechanism promot-
ing the lamellar-to-inverted hexagonal lipid-phase transition
(198). Despite these data indicating a role of cardiolipin in the
regulation of cytochrome c mobilization and MOM permea-
bilization, events that are associated with cristae remodeling,
other evidence neglects this function. It has been suggested
that the remodeling of cristae is a required step in the release
of the inner pool of cytochrome c (278), and recent studies
correlated the disassembly of Opa1 oligomers, a structural
determinant of cristae morphology, with the remodelling of
cristae (99). Hence to account for the rapid and extensive re-
lease of cytochrome c during apoptosis, it has been shown that
cristae are remodeled such that cytochrome c is redistributed
in the mitochondria before translocation through the MOM.
However, by using fluorescence microscopy followed by
three-dimensional electron-microscope tomography, it was
found that cristae remodeling was not required for efficient
release of cytochrome c (294). Moreover, besides its putative
role in cytochrome c mobilization, recent studies provided
evidence for a novel role for cardiolipin acting as an essential
activating platform for caspase-8 on mitochondria (118). In
type II cells, TNF or Fas caused the translocation of caspase-8
to mitochondria, where it binds to cardiolipin, resulting
in the oligomerization and activation of caspase-8. Because in
type I cells, DISC assembly and caspase-8 activation by death
ligands occur in specific domains of the plasma membrane,
lipid rafts, it is conceivable that the new role of mitochondria
in activating caspase-8 may also take place in raftlike do-
mains, which requires further investigation. Whereas these
findings are of significance in disorders in which tafazzin, a
mitochondrial transacylase enzyme required for cardiolipin
maturation, is mutated, such as in the Barth syndrome, the
relevance of this novel function of cardiolipin to anchor
caspase-8 to mitochondria in liver diseases remains to be
established.
Another interesting role of GSH in cell-death regulation
was described recently in neurons and cancer cells through
the redox inactivation of cytochrome c (311). The proapoptotic
activity of cytochrome c is influenced by its redox state, so
that increased ROS following an apoptotic insult leads to the
oxidation and hence activation of cytochrome c. Thus, this
novel finding suggests that even a modest increase in ROS
can prime cells to undergo apoptosis in response to other-
wise potentially nonlethal events of mitochondrial damage
and cytochrome c release. Hence, these emergingmechanisms
related to cardiolipin and cytochrome c redox regulation may
be dependent on mGSH, pointing to this antioxidant as a
critical therapeutic target for the control of cell death and
oxidative stress–related diseases (201).
D. Redox control of caspases
In addition to the redox modulation of cardiolipin and
cytochrome c, another level of apoptosis regulation is through
the redox control of caspases. Caspases are a growing family
of cysteine proteases that play a critical role during apoptosis.
Their name refers to the active cysteine group and the char-
acteristic cleavage of their targets at aspartate residues. The
presence of a cysteine moiety in the catalytic site is essential
for their function, as its replacement by other amino acids
results in loss of function (325). As with many other proteins,
the enzymatic activity of caspases is regulated by the redox
state of the cysteine residue (129, 306). As described in Jurkat
cells after Fas challenge, caspase-3 activity exhibited a dual
regulation, depending on the extent of ROS generation by
hydrogen peroxide. In an oxidizing state induced by a high
dose of hydrogen peroxide, caspase-3 became inhibited be-
cause of the oxidation of the critical cysteine residue (129).
Another mechanism of redox caspase regulation is by nitric
oxide and the subsequent S-nitrosylation of the active-site
thiol (219). In addition to directly modulating caspase-3 ac-
tivity, ROS have been described to regulate the processing
of the caspase-3 proenzyme, by regulating the activity of
caspase-9 (235, 306). Furthermore, recent findings have shown
the regulation of caspase-1 by superoxide dismutase 1 (211).
SOD1-deficient macrophages exhibited higher superoxide
anion generation, decreased redox potential, and inhibited
caspase-1 by reversible oxidation and glutathionylation of the
redox-sensitive residues Cys397 and Cys362. As a consequence
of the redox regulation of caspases, the apoptotic phenotype is
compatible with low to moderate oxidative stress, whereas
high doses of ROS shift cell death toward necrosis. As many
forms of liver diseases are accompanied with a burst of ROS
and subsequent oxidative stress, therapeutic strategies using
caspase inhibitors may be of limited value, as they may pre-
vent the acquisition of an apoptotic phenotype without effi-
ciently protecting against ROS-mediated necrosis.
VII. Lipid-Mediated Reactive Oxygen Species
Generation and Liver Diseases
Lipids such as sphingolipids (SLs), cholesterol, and free
fatty acids are integral components of biologic membranes
that play a major structural role. However, recent evidence
has shown that these lipids are more than just structural
membranes components. Thus, lipids actively participate in
1308 MARI ET AL.
and regulate signaling pathways and ROS generation, po-
tentially contributing to cell-death susceptibility. In particu-
lar, cholesterol and SLs are not randomly distributed within
membranes, but are concentrated in specific domains called
lipid rafts, where specific signaling pathways occur (309). In
this section, we briefly describe their mechanism of action
linked to oxidative stress, ROS generation, and the role in
hepatocellular injury.
A. Sphingolipids
SLs constitute a class of lipids that function as second
messengers in different cellular processes such as cell differ-
entiation, growth, and cell death (166, 224). Ceramide is the
prototypic SL that has been most intensively studied in rela-
tion to cell death and stress response. Ceramide levels increase
before the onset of cell death, arguing in favor of ceramide
upregulation as a cause rather than a consequence of cell
death (133). Among the different known cellular targets, cer-
amide has been shown to disrupt mitochondrial electron flow
at complex III, resulting in enhanced ROS generation, which
facilitates cytochrome c release and caspase activation (108,
123). Cellular ceramide levels can increase by several mech-
anisms. In addition to the de novo synthesis through activation
of serine-palmitoyl transferase, the rate-limiting enzyme in
ceramide synthesis, or ceramide synthetase, ceramide can
arise from hydrolysis of sphingomyelin-engaging sphingo-
myelinases (SMases) (166, 224) (Fig. 7). This pathway may be
of significance in promoting specific macrodomain formation
in the plasma membrane, allowing oligomerization of certain
cell-surface proteins such as TNF and Fas (66). Several SMases
have been characterized, two of which are of particular rele-
vance in cell signaling. The membrane-bound neutral SMase
(NSMase), with an optimum pH of*7.5, and an acidic SMase
(ASMase), with an optimum pH of *4.8, are further sub-
classified as an endosomal=lysosomal ASMase and a secretory
Zn2þ-dependent SMase (200, 224). Apoptotic stimuli, such as
death ligands (e.g., Fas and TNF), chemotherapeutic agents or
ionizing radiation activate these SMases, which account for
the ability of the inducing stimuli to generate ceramide with
different kinetics and possibly at distinct intracellular loca-
tions. Although the precise intracellular site of ceramide
generation by individual SMases remains to be clearly estab-
lished, the domains within the intracytoplasmic region of
the death-ligand receptor responsible for the activation of
NSMase and ASMase are different (166). Conflicting data on
the role of ceramide and SMases in cell-death signaling have
been published (277). For instance, NSMase is activated
through FAN (factor associated with NSMase) and leads to
the accumulation of ceramide at the plasma membrane;
however, its role in TNF-mediated cell death remains unclear
(105, 278). Activation of ASMase is dependent on TNFR1 in-
ternalization and is mediated through the death domain of
TNFR1 by the recruitment of the adaptor proteins TRADD
and FADD (277). A role for ASMase in transmitting apoptotic
signals of death receptors has been reported for TNF (105, 136,
137), Fas ligand (27, 53), and TRAIL (87). Inhibition of the
formation of clathrin-coated pits blocks the activation of the
endolysosomal ASMase and JNK, as well as TNF-induced cell
death. In contrast, inhibition of TNFR1 internalization does
not affect the interaction of the adaptor molecules FAN and
TRADD with TNFR1 at the cell surface, the activation of
plasma-membrane–associated NSMase, or the stimulation
of proline-directed protein kinases. The role of ASMase in
cell death has been shown to involve two distinct mecha-
nisms, including the recruitment of mitochondria through
ganglioside GD3 generation (106), and the downregulation of
liver-specific methionine adenosyltransferase-1A (MAT1A),
FIG. 7. Ceramide metabo-
lism. Scheme depicting the
different pathways that lead
to the generation (e.g., de novo
synthesis in the endoplasmic
reticulum and hydrolysis of
sphingomyelin by sphingo-
myelinases), or catabolism
(e.g., synthesis of gangliosides
in the Golgi, and generation
of ceramide-1-phosphate and
sphingosine-1-phosphate) of
ceramide.
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the rate-limiting enzyme responsible for the synthesis of S-
adenosyl-l-methionine (SAM) (Fig. 8) (199). In addition to
recruiting mitochondria to stimulate ROS generation, MOM
permeabilization, and cytochrome c release (107, 260), gan-
glioside GD3 has been shown to prevent the nuclear translo-
cation of DNA binding competent members of NF-kB, thus
disabling survival factors and sensitizing hepatocytes to TNF-
mediated cell death (60). Interestingly, Garofalo et al. (112)
suggested the existence of lipid microdomains composed of
GD3=Bax in mitochondria from T cells. Whether these mi-
crodomains exist also in liver mitochondria has not been
reported yet, and it deserves further research. As a key in-
termediate of TNF=Fas, ASMase contributes to hepatocyte
apoptosis, thus emerging as a novel therapeutic target for liver
diseases (see later).
B. Cholesterol
Cholesterol is a critical component of biologic membranes,
which plays an essential role in determining membrane
physical properties and in the regulation of multiple signaling
pathways (103, 146). Cholesterol is distributed to different
membranes, most prominently to plasma membrane, where
it participates in the physical organization of specific do-
mains. Mitochondria are considered cholesterol-poor organ-
elles and obtain their cholesterol load by the action of
specialized proteins involved in cholesterol delivery from
extramitochondrial sources followed by regulated trafficking
within mitochondrial membranes (Fig. 9) (103). Because of its
structural role in membrane dynamics, the homeostasis of
cholesterol is highly regulated, as its accumulation in cells is
toxic and causes fatal diseases. For instance, Niemann-Pick
type C (NPC) disease is a fatal neurodegenerative disease
characterized by lysosomal storage of cholesterol and glyco-
sphingolipids. Although most patients with NPC exhibit
neurologic symptoms, cholesterol accumulates in the liver
and pancreas, and some patients die early of liver failure be-
fore manifestations of the neurologic symptoms. Moreover,
NPC disease is the second most common cause of neonatal
cholestasis. Ten percent of NPC infants with neonatal chole-
stasis die of liver failure before they reach 6 months of age,
and patients who survive often live with persistent liver dis-
ease accompanied by fibrosis, and, in some rare cases, cir-
rhosis. Recent studies in NPC-1–deficient mice showed that
hepatocyte apoptosis is a primary cause of liver dysfunction
and liver failure (19). In addition, recent data demonstrated a
key role for TNF in NPC-1 deficiency–mediated hepatocyte
apoptosis (259). These data suggest that cholesterol accumu-
lation in NPC sensitizes to TNF-induced hepatocellular cell
death. Although the molecular mechanisms underlying these
observations are not completely understood, recent findings
have shown that free cholesterol in NPC-1–deficient hepato-
cytes accumulates in mitochondria but not in endoplasmic
reticulum, resulting in a selective mGSH depletion and sub-
sequent sensitization to TNF-mediated cell death by over-
generation of mitochondrial ROS (197) (Fig. 10). Although
hepatic mitochondrial cholesterol fulfills an important phys-
iological function, such as bile acid synthesis, its over-
accumulation in mitochondria impairs vital membrane
functions, including transport of GSH from the cytosol into
mitochondria, leading to mGSH depletion (96, 189). Con-
sistent with the selective accumulation of mitochondrial
cholesterol in NPC disease, this particular pool of cholesterol
has emerged as an important factor in steatohepatitis through
mGSH depletion (Fig. 11). However, the mechanisms under-
lying the mitochondrial cholesterol loading in hepatic stea-
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FIG. 8. Dual role of GD3 in cell death. Ganglioside GD3,
generated after activation of acid sphingomyelinase, has
been shown to promote cell death by two different mecha-
nisms: GD3 is able to migrate to the mitochondria, where it
generates ROS, cytochrome c release, and cell death; con-
versely, GD3 downregulates the liver-specific methionine
adenosyltransferase-1A (MAT1A), the rate-limiting enzyme
responsible for the conversion of methionine (Met) into
S-adenosyl-l-methionine (SAM), a GSH precursor, leading to
the depletion of GSH, and therefore to an increased suscep-
tibility to cell death.
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FIG. 9. Cellular cholesterol synthesis and transport.
Cholesterol is synthesized in the endoplasmic reticulum (ER)
and distributed to different membranes, principally to the
plasma membrane, bypassing the Golgi. In addition, cho-
lesterol from the ER or coming from endosomes (through
low-density lipoprotein receptor–mediated cholesterol up-
take) also can be targeted to the mitochondria through the
action of a cholesterol-transfer protein, steroidogenic acute
regulatory protein (StAR).
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tosis are currently unknown. In hepatoma cells, however, an
overexpression of StAR, a polypeptide involved in the in-
tramitochondrial trafficking of cholesterol, has been ob-
served (288). StAR silencing resulted in the net decrease of
mitochondrial cholesterol loading (222), suggesting its in-
volvement in the delivery of mitochondrial cholesterol, be-
sides its role in intramitochondrial cholesterol trafficking.
Thus, given the impact of cholesterol-mediated changes on
membrane dynamics with subsequent regulation of mGSH
and ROS generation, a better understanding about the cell
biology and trafficking of this particular cholesterol pool
may be of relevance in themodulation of redox signaling and
cell death.
C. Free fatty acids and lipotoxicity
Since the first description in pancreatic b cells associated
with the impairment of insulin secretion, free fatty acids
(FFAs) are considered the main cause of lipotoxicity, with
saturated FA (i.e., palmitate) being one of the most potent
triggers of lipotoxicity (180). Lipotoxic effects of FFA are of
relevance not only in type 2 diabetes, but also in the devel-
opment and progression of hepatic steatosis (4, 195). The
mechanisms and alterations in the cellular metabolism caused
by FFA are multifactorial, including activation of JNK, in-
duction of proinflammatory cytokines, inhibition of mito-
chondrial b-oxidation, increased ROS production, as well as
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FIG. 10. Role of free cholesterol in NPC-1–deficient hepatocytes. In normal hepatocytes, LDL-derived free cholesterol (Ch)
can be transported, in a process that involves NPC proteins, from the endosomes to the endoplasmic reticulum (ER), where it
is esterified to cholesteryl esters (ECs). However, in NPC-1–deficient hepatocytes, free cholesterol is not able to move to the
ER, and it accumulates in mitochondria, resulting in selective mGSH depletion.
FIG. 11. Mitochondrial cho-
lesterol in different patho-
logic settings. In normal cells,
overaccumulation of choles-
terol in mitochondria impairs
GSH transport from cytosol
to mitochondria, leading to
mitochondrial GSH depletion,
and consequently, to increased
sensitivity to cytokines such as
TNF and Fas, as observed in
hepatocytes from alcoholic-
(ASH) and nonalcoholic
(NASH) steatohepatitis exper-
imental models, in which
mGSH depletion was accom-
panied by increased mito-
chondrial ROS generation
and cardiolipin peroxidation.
However, in cancer cells, cho-
lesterol accumulation in mito-
chondria contributes to the
mitochondrial dysfunction of
cancer cells, favoring en-
hanced dependence on aero-
bic glucolysis for energy production. Remarkably, under these conditions, and in contrast to the effect observed in normal cells,
hepatocellular carcinoma cells were able to maintain optimal mGSH levels. This enhanced mitochondrial cholesterol was
accompanied by increased resistance to chemotherapy, Bax, and hypoxia, selectively acting through mitochondria.
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the generation of toxic lipid intermediates and lipid deriva-
tives (24, 81, 195). In particular, the generation of oxidative
stress is an important factor in lipotoxicity because of its
contribution to cellular stress signaling and interference with
mitochondrial functions (4). For instance, in a recent study,
palmitate was shown to limit GSH synthesis by inhibition of
the cysteine transporter and the subsequent limited sub-
strate supply (286). This outcome, coupled with the targeting
and impairment of mitochondrial function and subsequent
generation of ROS, suggests that mitochondrial oxidative
stress may be a primary mechanism of saturated FFAs, with a
negative impact on the intracellular redox state in different
subcellular organelles, including the ER, mitochondria, and
lysosomes (24, 92, 286). Palmitate-mediated induction of ROS
in hepatocytes can be prevented by inhibition of carnitine
palmitoyltransferase or the blocking of the mitochondrial
electron-transport chain (230). Another potential mechanism
involved in palmitate-induced lipotoxicity may relate to en-
hanced ceramide generation, as this sphingolipid is synthe-
sized de novo from palmitoyl CoA and serine in the ER (see
earlier; Fig. 7). A recent study showed that the lipotoxicity
induced by palmitate involved Bim upregulation through
transcription factor FoxO3A, which was not altered by fu-
monisin B1, an inhibitor of de novo ceramide synthesis (12).
However, the effect of this inhibitor on the homeostasis of
ceramide in hepatocytes after palmitate exposure was not
examined (12). Protein phosphatase 2A (PP2A) is a known
target of ceramide (264), and it has been shown that inhibition
of ceramide synthase by fumonisin B1 in vivo results in the
activation of other sphingolipid-metabolizing systems (e.g.,
SMase and SPT), contributing to an imbalance of the sphin-
golipid metabolism (135). It is, therefore, possible that in-
creased activity of SMase could compensate for reduced
cellular ceramide levels by production of ceramide through
sphingomyelin hydrolysis. Thus, these findings indicate that
the involvement of ceramide in FoxO3-dependent Bim ex-
pression and hepatic lipoapoptosis cannot be excluded and
deserves further investigation.
Finally, another factor contributing to palmitate-induced
lipotoxicity involves lysophophatidylcholine generation by
phospholipase A2 (131). Interestingly, palmitic acid–induced
hepatocyte death was accompanied by decreased cardiolipin
content, mitochondrial depolarization, and cytochrome c
release, events that were prevented by phospholipase A2 in-
hibition and reproduced by lysophosphotidylcholine admin-
istration. Moreover, oleic acid abrogated the toxic effects of
palmitic acid due to the diversion of palmitic acid to triglyc-
eride storage, resulting in decreased lysophosphotidylcholine
content. These findings suggest that FFAs lead to steatosis
or lipoapoptosis, depending on the abundance of saturated=
unsaturated FFAs by several mechanisms, including the
mitochondrial stimulation of ROS production.
VIII. Impact of ROS in Liver Diseases
Given the regulation of signaling pathways through redox
mechanisms, in this section, we briefly describe the impact of
oxidative stress and redox signaling in liver diseases.
A. Hepatitis and liver failure
Death receptors, in particular, TNF and Fas, are known to
mediate many forms of liver injury, including fulminant
hepatitis (196). The signal transduction of these ligands with
their binding to the corresponding plasma membrane recep-
tors is complex and includes protein–protein interactions
and the generation of second messengers, such as sphingoli-
pids that control the balance between the survival and pro-
death signals generated by either ligand. As described earlier,
an important player is the overgeneration of ROS, which can
subsequently regulate JNK activation (198, 158, 315). Nor-
mally, JNK activation in response to TNF is transient because
NF-kB diminishes its activation (29, 158). Thus, NF-kB sup-
pression sensitizes hepatocytes to TNF by allowing sustained
JNK activation through ROS generation. NF-kB controls the
magnitude of ROS generation after TNF by inducing the ex-
pression of MnSOD and the ferrritin heavy chain (158, 198,
249). An important source of TNF-mediated ROS production
is the mitochondrial complex III, which is targeted by cer-
amide derived fromASMase (105, 108, 197, 198). In acute liver
inflammation and liver failure, JNK activation induces apo-
ptosis by targeting distinct factors upstream of the mito-
chondrial death pathway, among which Itch and Bid play
central roles (41). JNK phosphorylates and activates Itch, an
E3 ubiquitin ligase. The active Itch catalyzes the ubiquitina-
tion of c-FLIPL that subsequently leads to its proteosomal
degradation. Moreover, JNK also translocates to mitochon-
dria,where itmight directly trigger the release of cytochrome c
(6). Fulminant hepatitis inmice can be inducedwith treatment
with the lectin concanavalin A by a TNF-dependent mecha-
nism, as shown in mice deficient in both TNFR1 and TNFR2,
that requires JNK (41, 158). Two JNK isoforms, JNK1 and
JNK2, are expressed in the liver. However, their relative
contribution to TNF-mediated hepatitis is currently unsettled.
For instance, recent findings indicated that jnk2-=- hepatocytes
are resistant to TNF-induced apoptosis, as compared with
wild-type or jnk1-=- hepatocytes, by a mechanism involving
jnk1-mediated expression of the antiapoptotic gene Mcl-1
(164, 165). Deletion of Mcl-1 in jnk2-=- hepatocytes increases
TNF and galactasomine=LPS-induced hepatocellular apopto-
sis and liver injury in vivo. Whereas these findings indicated
that jnk1 plays a critical role in determining TNF-mediated
hepatocellular apoptosis, Das et al. (72) showed that deletion
of both jnk1 and jnk2 in hepatocytes did not prevent TNF-
mediated hepatocellular apoptosis and liver failure in vivo. In
contrast, mice with loss of jnk1 and 2 in hematopoietic cells
exhibited a profound defect in hepatitis that was associated
with reduced expression of TNF (72). Thus, in addition to the
individual role of jnk1 and jnk2 in TNF-mediated hepatitis,
their site of generation appears to be critical in determining
the final outcome in the susceptibility of hepatocytes to TNF.
Nevertheless, these findings confirm a role for JNK in the
development of hepatitis and also provide compelling evi-
dence pointing to hematopoietic cells as the sites of the es-
sential function of JNK. In addition to JNK, another critical
mediator of TNF=Fas-mediated hepatocellular death and
fulminant liver failure is ceramide generation, particularly
through ASMase activation (105, 199). In these studies, it was
shown that mice deficient in ASMase but not in NSMase are
resistant to galactosamine plus TNF or LPS-induced hepato-
cellular injury, characterized by the mitochondrial generation
of ROS and MAT1A downregulation and consequent SAM
depletion. As mentioned earlier, decreased SAM levels by
TNF caused GSH depletion, contributing to TNF-induced
ROS overgeneration. Importantly, SAM therapy was able to
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rescue mice from galactosamine plus TNF-mediated liver
failure (199), and most of this effect was mediated by the
ability of SAM to replenish the mitochondrial pool of GSH.
B. NASH and alcohol-induced liver injury
Steatohepatitis (SH) represents an advanced stage in the
spectrum of fatty liver diseases that encompasses alcoholic
(ASH) and nonalcoholic steatohepatitis (NASH), two of the
most common forms of liver diseaseworldwide. Although the
primary etiology of ASH and NASH is different, these two
diseases show almost identical histologic features character-
ized by steatosis, inflammation (predominantly characterized
by leukocytes and mononuclear cells infiltration), and hepa-
tocellular cell death due to sensitivity to oxidative stress (5).
Despite significant progress in recent years, the pathogenesis
of SH is still incompletely understood and, in particular,
the mechanisms that determine the transition from simple
steatosis to SH and hence disease progression. Several inter-
related factors contribute to disease progression, including
insulin resistance, hepatic fat accumulation, inflammation,
and oxidative stress (203). The accumulation of lipids in the
cytoplasm of hepatocytes, mostly in the form of FFAs and
triglycerides, is considered the first step in the development of
SH. However, SH progression beyond hepatic steatosis usu-
ally does not occur in the absence of a second hit that pro-
motes oxidative stress, inflammation, cell death, and fibrosis.
In this regard, cytokine overexpression and the membrane
receptors have been shown to contribute to hepatocellular
apoptosis and SH (5, 67, 91). TNF is overexpressed in the
livers of obese mice and mediates insulin resistance in both
diet-induced and genetic models of obesity (143). Recent
findings by usingmice deficient in both TNF receptors 1 and 2
showed a critical role for TNF signaling in diet-induced
NASH (300). Thus, understanding the factors that determine
the susceptibility of the fatty liver to TNF is of potential sig-
nificance. Although the two-hit hypothesis is the most prev-
alent view to explain disease progression, recent findings
provided evidence that the type rather than the amount of
fat is critical in the sensitization of the fatty liver to TNF=
Fas-mediated steatohepatitis (197). By using nutritional and
genetic models of hepatic steatosis, it was described that
cholesterol accumulation in hepatocytes, as opposed to tri-
glycerides or FFA, played a critical role in NASH (197, 207).
Although cholesterol loading occurred in different cell sites,
cholesterol accumulation in the ER or the plasma membrane
did not cause ER stress or alter TNF signaling. Rather, the
trafficking of cholesterol to mitochondria accounted for the
hepatocellular susceptibility to TNF due to mGSH depletion
(Fig. 11). These findings were not only observed in mice fed a
hypercholesterolemic diet but also were observed in NPC-
1–deficient mice as well as in obese ob=ob mice. Boosting the
pool of mGSH or preventing its depletion by blocking cho-
lesterol synthesis with atorvastatin attenuated the suscep-
tibility of obese ob=ob mice to LPS-mediated liver injury,
highlighting the relevance of mitochondria-mediated oxida-
tive stress in the susceptibility to TNF-induced liver injury
and NASH. Furthermore, a correlation between cholesterol
accumulation and disease progression was described recently
in morbidly obese patients (30). Interestingly, in this patient
population, they found a significant overexpression of StAR, a
polypeptide involved in the mitochondrial delivery of cho-
lesterol (222, 288), and SREBP-2, a transcription factor that
controls the de novo cholesterol synthesis, compared with
healthy controls or patients with simple steatosis.
In addition to cholesterol, SLs also may play a role in
NASH. Blocking glucosylceramide synthase, the first step in
glycosphingolipid synthesis from ceramide, ameliorated he-
patic steatosis and increased insulin sensitivity in obese mice
(340), indicating a role for glycosphingolipids in NASH. Be-
cause GD3 is known to target mitochondria (see earlier)
causing ROS generation, further research on the potential role
of GD3 in NASH is needed.
Similar to these findings with NASH, TNF plays a key role
in alcohol-induced liver injury, which is characterized by the
susceptibility to TNF-mediated cell death (58, 145, 246, 335).
Although the mechanisms for the transition from resistance to
susceptibility to TNF with alcohol intake may be multifacto-
rial, including elevated PTEN levels (283), it has been reported
that alcohol feeding causes mGSH depletion because of
alcohol-stimulated cholesterol synthesis (59, 61, 96, 189).
Cholesterol accumulation in mitochondrial membranes im-
pairs the hepatic mitochondrial transport of GSH from the
cytosol, resulting in its depletion (59, 61, 323, 341), with sim-
ilar findings observed in alveolar type-II cells (312). mGSH
has been associated with increased susceptibility to ethanol-
induced liver injury and lethality in mice deficient in Nrf2, a
transcription factor that regulates GSH biosynthesis and
homeostasis (176). The mechanism involved in the mGSH-
dependent hepatocellular susceptibility to TNF=Fas after
mGSH depletion involved mitochondrial generation of ROS
through ASMase-induced ceramide production, causing the
peroxidation of cardiolipin, which facilitated the permeabi-
lizing activity of oligomerized Bax in the MOM (198). Re-
markably, the potentiating effect of peroxidized cardiolipin
did not involve modifications in the oligomerization or pen-
etration of active Bax in the bilayer; instead, the presence of
peroxidized cardiolipin restructured the lipid bilayer, indi-
cating that this lipid facilitates the formation or expansion
or both of the proteolipidic pore itself. Another interesting
finding was that alcohol feeding induced the depletion of the
mitochondrial pool of SAM (94). As mentioned earlier, the
transulfuration pathway provides cysteine from methionine
for the synthesis of GSH through generation of SAM (Fig. 12).
Both SAM and GSH share metabolic similarities, as both
are exclusively synthesized in the cytosol but are found in
the mitochondria as well, where they play pivotal roles in the
maintenance of mitochondrial functions (205). The time-
dependent analysis indicated that the mitochondrial SAM
depletion by alcohol feeding preceded that of mGSH. More-
over, unlike alcohol-induced cholesterol loading in mito-
chondria, which impaired the transport of GSH from the
cytosol, the mitochondrial transport of SAM was insensitive
to alcohol-mediated changes in membrane dynamics (94).
Rather, the mechanism of mitochondrial SAM depletion
by alcohol feeding involved cytosolic SAM limitation and
S-adenosylhomocysteine accumulation, which competed for
SAM to be transported to the mitochondria. In addition to the
critical role of SAM in methylation reactions, another preva-
lent mechanism of action is the modulation of membrane
fluidity through phosphatidylcholine synthesis from phos-
phatidylethanolamine (109). Hence, the earlier depletion of
mitochondrial SAM by alcohol intake can contribute to that of
GSH, suggesting that strategies to preserve this pool of SAM
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may be of potential relevance in alcohol-induced liver injury
by protecting hepatocytes from TNF-induced liver injury due
to the maintenance of mGSH stores. In contrast to this po-
tential therapeutic effect of SAM, the use of N-acetylcysteine
in the face of alcohol consumption has been shown to be
inefficient in boosting mGSH levels, despite significantly in-
creasing those of cytosolic GSH (109), underlying the im-
pairment in the transport of GSH into mitochondria imposed
by cholesterol accumulation in mitochondria.
In addition to these mechanisms, another key player in
NASH and alcohol-induced liver injury is ER stress, which
contributes to lipogenesis, fatty liver, and hepatocellular in-
jury (160). Among the several branches that constitute this
pathway, XBP-1, a transcription factor that belongs to the
bZip family and is activated by accumulating unfolded pro-
teins in the ER, plays an essential role in the control of ER
stress (241). With ER stress, the spliced XBP-1 regulates a
subset of ER-resident chaperone genes to protect cells from ER
stress. Interestingly, in addition to this established role, a
novel function of XBP-1 in the regulation of hepatic lipogen-
esis has been described (178). XBP-1 protein expression in
mice was elevated after a carbohydrate-enriched diet feeding
that corresponded with the induction of critical genes in-
volved in fatty acid synthesis. However, inducible and se-
lective depletion of XBP-1 in the liver resulted in marked
hypocholesterolemia and hypotriglyceridemia, secondary to
a decreased production of lipids from the liver, demonstrating
a novel function for XBP-1 in the regulation of lipogenesis and
fatty liver. Remarkably, this phenotype was not accompanied
by hepatic steatosis or impairment in protein secretory func-
tion. Moreover, a protective role for XBP-1 against oxidative
stress was recently described in XBP-1–deficient embryonic
fibroblasts (184). In XBP-1–deficient cells, hydrogen peroxide
induced more-extensive ROS generation and prolonged p38
phosphorylation than in wild-type cells. Interestingly, the
expression of different antioxidant enzymes, including cata-
lase, was lower in XBP-1–deficient cells, suggesting a novel
role for this transcription factor in oxidative-stress regulation.
Thus, the role of XBP-1 in fat accumulation and oxidative
stress in NASH and alcohol-induced liver injury should be
further investigated. Nevertheless, these findings defining
XBP1 as a regulator of lipogenesis may have important im-
plications, suggesting that the targeting of this ER protein
may be a promising approach for the treatment of fatty liver
disease.
Finally, another aspect that may regulate fatty liver disease
is the activation or recruitment or both of hepatic stem cells to
the site of injury. Hepatic stem cells have attracted attention as
potential candidates for liver-directed gene therapy and re-
generative medicine. Although hepatic stem cells are known
to contribute to liver regeneration when proliferation of
hepatocytes is impaired or in the face of significant tissue
damage, the mechanisms controlling lineage commitment
and response of hepatic stem cells to environmental signals
remain poorly defined. In alcohol-fed and obese ob=ob mice,
it was shown that the expansion of hepatic oval cells helps to
compensate for the increased turnover of damaged mature
hepatocytes, thus limiting the progression of fatty liver disease
(332). Given the relevance of TNF in NASH and alcohol-
mediated liver injury through ROS overgeneration, the sus-
ceptibility of hepatic progenitor cells to TNF may be a critical
factor involved in disease progression. In this regard, it was
shown that differentiated hepatic progenitor cells (rat liver
epithelial cells) are more susceptible to TNF-mediated apo-
ptosis accompanied by ROS overproduction and GSH de-
pletion (269). Furthermore, a correlation between the degree
of oval cell activation and extent of oxidative damage in mice
and humans with fatty livers was described (262), suggesting
a survival advantage against oxidative stress. In addition, the
upregulation of stress-inducible genes, such as acute-phase
reactants (APRs) may limit tissue damage in response to
stress, inflammation, or oxidative stress. The acute-phase re-
action is characterized by altered transcription (positive or
negative) of numerous target genes, many of which are ex-
pressed exclusively or predominantly by the liver to regulate
diverse processes such as blood coagulation, innate immu-
nity, metal sequestration, or antiproteolytic activities. Taken
together, it appears that oxidative stress plays a dual role in
regulating hepatic progenitor cells, stimulating recruitment
and apoptosis resistance at early stages of activation that
culminate in apoptosis susceptibility in differentiated cells.
C. Ischemia=reperfusion liver injury
and liver transplantation
Hepatic ischemia=reperfusion (I=R) damage can occur
in diverse clinical settings, including liver transplantation,
trauma, hemorrhagic shock, or liver surgery, and is a serious
clinical complication that may compromise liver function
because of extensive hepatocellular loss. Despite intensive
research in this area, the cellular and molecular mechanisms
responsible for hepatic I=R injury are not well understood.
Molecular events include NF-kB activation, JNK activation,
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FIG. 12. The transsulfuration pathway. Dietary methio-
nine is converted to the methyl donor S-adenosylmethionine
(SAM) and is demethylated to S-adenosylhomocysteine
(SAH) and homocysteine. In the transsulfuration pathway,
homocysteine is converted to cystathionine that can be
transformed into cysteine. Cysteine, in turn, can be used in
glutathione (GSH) synthesis. Homocysteine also can be re-
methylated to methionine, either through the folate cycle by
using 5,10-methylenetetrahydrofolate (5-MTHF) involving
the enzyme methionine synthase (MS), or by using betaine
and the enzyme betaine homocysteine methyltransferase
(BHMT). Both GSH and SAM can be transported to the mi-
tochondria; however, whereas cholesterol loading in the
mitochondria inhibits GSH transport, mitochondrial SAM
transport is insensitive to membrane dynamics.
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mitochondrial dysfunction followed by ROS generation, and
the activation of Toll-like receptors (TLR). Although this
family of receptors is known to play a fundamental role in
innate immunity and inflammation, recent evidence showed
that TLR, particularly TLR4, is an important mediator of
hepatic I=R injury through an interferon regulatory factor-3–
dependent pathway (337). Moreover, deficiency of TLR4
signaling in the donor organ has been shown to reduce I=R
injury in a murine liver-transplantation model (282). Early
protein targets of I=R during liver transplantation have been
described by using differential proteomic analysis (271). Be-
sides a cluster of proteins functionally involved in lipid, en-
ergy, andmetabolic pathways, the active-site thiol of PrxI was
found to be overoxidized into sulfonic acid, indicating that
the redox state of Prx may be an early and sensitive marker
of oxidative stress in hepatic I=R and liver transplantation
(37, 310). Although these factors may allow the design of
biochemical and genetic strategies to modulate hepatic I=R
injury, ischemic preconditioning is a surgical strategy of ther-
apeutic value during I=R, involving a number of mechanisms,
including the redox-sensitivemitochondrial ATP-sensitive Kþ
channels that control ROS production (90, 221).
TNF has been identified as a key player in hepatic I=R
damage (263). Consistent with these findings, ischemic pre-
conditioning with TNF=Fas was shown to reduce ischemic
injury in the liver through the activation of oxidative stress
that induces a cytoprotective response (152). In line with its
role in TNF=Fas signaling, it was shown that ASMase plays
a role in hepatic I=R injury (186). Indeed, ASMase-induced
ceramide generation targeted mitochondria through JNK and
BimL activation. Thus, in addition to the previously described
mechanisms and consistent with the role of ceramide in re-
cruiting the mitochondrial pathway of cell death, ASMase
emerges as a potential target for intervention against he-
patic I=R.
The role of NF-kB and ROS in hepatic I=R injury is of in-
terest, with the former playing a controversial role because of
its dual action in the induction of survival=inflammatory
genes. Whereas the generation of ROS during I=R derives
from various sources, mitochondrial ROS constitute a pre-
dominant mechanism in this condition, as examined in vivo
with two-photon confocal microscopy (Fig. 13). Hepatic NF-
kB activation has been shown to diminish hepatic I=R injury
and improve orthotopic liver transplantation, whereas NF-kB
inactivation has been shown to protect against hepatic I=R
(172, 293). These apparently conflicting results have been ex-
plained on the basis of different degree of residual NF-kB
activation. Moreover, ROS and oxidative stress exert a dual
effect on NF-kB activation, which involves its release from
the inhibitory moiety in the cytosol, its nuclear translocation,
and the subsequent transactivation of target genes. Recent
data showed that NF-kB transactivation is diminished in
FIG. 13. Mitochondrial ROS generation during hepatic ischemia=reperfusion (I=R) injury. In vivo two-photon confocal
microscopy during partial (70% of the liver) hepatic I=R (90min of ischemia followed by 60min of reperfusion) in mice. The
generation of ROS, by using 2’,7’-dichlorofluorescin (DCF) fluorescence, occurs largely in mitochondria and is accompanied
by loss of mitochondrial membrane potential, as detected by using tetramethylrhodamine ethyl ester (TMRE). The imaging of
the liver of living mice was performed by the using spectral confocal inverted microscope Leica TCS SP5. DCF (200mM,
incubated for 45min) and TMRE (5mM, incubated for 30min) labelings were imaged by using one-photon excitation at
485 nm and emission at 520 nm for the DCF and excitation at 516 nm and emission at 582–677 nm for the TMRE. The
emissions were acquired with internal spectral detector (PMT) at high speed to avoid the movement from animal breathing
and heart beating during acquisition. (For interpretation of the references to color in this figure legend, the reader is referred
to the web version of this article at www.liebertonline.com=ars).
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hepatocytes after GSH depletion, involving IKK-dependent
and -independent mechanisms (191). Moreover, GSSG for-
mation subsequent to the overgeneration of ROS inactivates
NF-kB (85). In addition to this dual behavior, the activation of
NF-kB in different population of cells in the liver also may
contribute to the dichotomy of NF-kB in I=R-induced liver
injury. Recent findings showed that ROS mediate liver injury
through selective parenchymal inactivation of NF-kB in I=R
(187). Thus, whereas in hepatocytes, the activation of NF-kB
after I=R occurred through a noncanonic pathway without
IkB degradation through Src activation, in Kupffer cells, this
process involves a canonic pathway likely mediated by TLR.
These findings have strong implications, as they suggest that
strategies that increase GSH in hepatocytes would maintain
NF-kB activation and hence the expression of survival genes
without changing the induction of proinflammatory cyto-
kines, whichmay thus contribute to the protection against I=R
damage. In contrast, marked GSH depletion resulted in the
downregulation of survival genes and in the enhanced gen-
eration of TNF=IL-1b, which translated into exaggerated liver
damage after I=R.
D. Cholestasis and bile acid–induced liver injury
Cholestatic liver disease is a prominent cause of morbidity
and mortality because of the retention of toxic bile acids,
which are known to play a key role in cell toxicity (233, 334).
Chronic retention of toxic bile acids can cause oxidative stress,
apoptosis, and fibrosis, leading to cirrhosis. The role of GSH
in cholestatic liver diseases is controversial, although most
studies have shown that experimental cholestasis in rats and
hepatocytes subjected to toxic bile acids results in a decrease
in GSH levels (233, 261). Moreover, other mechanisms in-
volved in bile acids–induced cytotoxicity include ER stress
(298) and mitochondrial targeting (334), which can further
limit antioxidant defense and contribute to liver injury. Bile
duct ligation in rats was reported to cause mitochondrial
dysfunction and ROS generation, events associated with in-
creased cholesterol=phospholipids in mitochondria (168). In-
terestingly, elevated mitochondrial volume per hepatocyte
was described in perfused liver from bile-duct–ligated rats,
which constitutes an adaptive mechanism to offset the im-
pairment in mitochondrial metabolism during secondary
biliary cirrhosis (169).
Another mechanism that can contribute to ROS over-
generation relates to decreased glutamate cysteine ligase
(GCL) expression and activity by bile acids (233). Remarkably,
ursodeoxycholic acid, which is currently in use for the treat-
ment of primary biliary cirrhosis, was shown to prevent the
decrease in GCL expression during chronic cholestasis and
to increase GCL expression in cultured rat hepatocytes (217).
Furthermore, its taurine derivative may have far-reaching
effects in GSH regulation, other than modulating GCL ex-
pression. For instance, tauroursodeoxycholic acid has been
shown to preserve membrane dynamics, preventing the de-
pletion of mGSH after alcohol feeding (56) and to alleviate ER
stress in type-2 diabetes (241). In this regard, and consistent
with cholesterol enrichment in mitochondria, secondary bili-
ary cirrhosis has been reported to deplete mGSH levels (167).
However, the therapeutic effect of tauroursodeoxycholic acid
in secondary biliary cirrhosis in relation to its ability to pre-
vent mGSH depletion by bile acids remains to be fully es-
tablished. Thus, the therapeutic effect of ursodeoxycholic acid
and its taurine derivative may be multifactorial. The balance
between hydrophobic and hydrophilic bile acids determines
the onset of liver disease through mechanisms involving mi-
tochondria=ER targeting, oxidative stress, and the limitation
in antioxidant defense, including mitochondrial GSH. Con-
sequently, this disorder is potentially susceptible for the
beneficial effects of antioxidants, although this remains to be
fully established.
E. Endotoxemia
The liver plays a key role in the clearing of gut-derived
lipopolysaccharide (LPS), a major component of the outer
membrane of all gram-negative bacteria that can trigger the
synthesis and release of proinflammatory cytokines such as
TNF-a, interleukin 1b (IL-1b), and inducible nitric oxide syn-
thase (iNOS) (292, 338). A major mechanism of LPS-mediated
effects is the activation of NF-kB through TLR (339), although
NADPH oxidase–induced ROS also has been reported to
contribute to endotoxin-mediated liver injury (124). Endo-
toxemia frequently occurs in patients with liver cirrhosis, with
the extent of endotoxemia correlating with the degree of liver
failure. Moreover, endotoxemia also is believed to participate
in the pathogenesis of many liver diseases, including alcoholic
liver disease andNASH, inwhich TNF plays a central role (67,
145). Consistent with the involvement of oxidative stress after
LPS exposure, GSH has been shown to play an important
role in the susceptibility to LPS-induced liver injury (247). For
instance, in experimental models, LPS has been reported to
deplete GSH stores in the liver, and mice deficient in GSHPx
exhibited enhanced susceptibility to LPS-mediated liver
damage (149). Consistent with these findings, the exogenous
administration of GSH has been shown to decrease LPS-
induced systemic inflammatory response and mortality (295).
The molecular mechanism underlying the protective effect of
GSH relates to the modulation of TLR4 signaling and the
potentiation of LPS-induced TNF secretion under low-GSH
status. Consequently, Nrf2-deficient mouse embryonic fibro-
blasts exhibited greater activation of NF-kB and interferon
regulatory factor 3 in response to LPS and polyinosinic-
polycytidylic acid [poly(I:C)] stimuli (299), indicating a critical
role for Nrf2 in the regulation of GSH to modulate optimal
NF-kB activation in response to LPS and TNF. The down-
regulation of GSH levels by LPS involves severalmechanisms,
including its depletion as a consequence of oxidative stress
(338), an event that may be due to the reduction of GCL ac-
tivity during endotoxemia because of its decreased expression
(247). Moreover, inhibition of nitric oxide generation amelio-
rated the decrease in GSH, suggesting that the hepatic ex-
pression of GCL is inhibited by increased availability of NO
stores (247).
Despite these findings, the regulation of GCL by NO is not
well established and appears to depend on the cell type ana-
lyzed. For instance, NO did not influence the basal GSH levels
or GCL expression in rat hepatocytes, although IL-1 increased
the expression of GCL (173). These findings contrast with the
outcome observed in rat aortic vascular smooth muscle cells,
in which NO increased GSH levels and the expression of both
subunits of GCL (218). Thus, although the regulation of GSH
during endotoxemia remains to be fully understood, the evi-
dence available suggests that prodrugs that boost GSH levels
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may be of therapeutic relevance. Further research is needed
to establish whether this beneficial effect of GSH is through
control of oxidative stress or modulation of proinflammatory
genes through NF-kB activation or both.
F. Hepatocellular cancer
Liver cancer constitutes the final stage in the progression of
chronic liver diseases; it is the fifth-greatest cause of cancer-
related death worldwide. Because current effective therapy is
lacking, an urgent need exists for a better understanding of
the molecular pathways regarding hepatocarcinogenesis
and the mechanisms involved in therapy resistance. One of
the prominent characteristics of solid tumors is the onset of
hypoxia along the edge of tumor growth. This anatomic
feature arises because of the disorganized structure and ar-
chitecture of tumor vasculature, resulting in irregular and
inefficient oxygen delivery, which is considered a negative
prognostic factor for response to treatment and survival of
cancer patients (80). In addition to the prominent role of
prolylhydroxylases as oxygen sensors, another critical player
is the mitochondrial generation of ROS after oxygen depri-
vation (28, 126). Hypoxia-induced mitochondrial ROS regu-
late HIF-1a stabilization and NF-kB activation (126, 188). In
particular, the NF-kB activation by hypoxia-induced mito-
chondrial ROS generation occurs by a noncanonic pathway
involving the phosphorylation of IkB in tyrosine residues
through activation of the c-Src tyrosine kinase (Fig. 14) (188).
With Src mutants, the cysteine 487 was identified as a criti-
cal determinant in the activation of Src by ROS. Although
this pathway involving Src–NF-kB activation in response to
hypoxia is essential for hepatocellular carcinoma cell survival,
the overproduction of mitochondrial ROS can be exploited to
destroy cancer cells by an oxidant-dependent mechanism
(188). In this regard, the depletion of mGSH has been shown
to potentiate the mitochondrial ROS generation by hypoxia,
resulting in necrotic cell death. Thus, whereas ROS promote
carcinogenesis through activation of both HIF1a and NF-kB,
its enhanced production by mGSH depletion emerges as an
attractive approach to killing cancer cells. Consistent with this
notion, it was observed that oncogenically transformed cells
are sensitive to the generation of ROS by b-phenylethyl iso-
thiocyanate, which depletes GSH in both cytosol and mito-
chondrial fractions and inhibits NF-kB activation (302).
Hence, mitochondrial ROS generation by hypoxia exhibits a
dual role in cancer biology: it fosters carcinogenesis by acti-
vating NF-kB and HIF1a, which, in turn, promote cancer cell
survival, angiogenesis, and tumor expansion; conversely, its
overproduction after mitochondrial GSH depletion switches
hypoxia from a cancer-promoting to a cancer-killing envi-
ronment. Finally, because GD3 has been characterized as a
proapoptotic lipid effector by a dual role involving mito-
chondria targeting and the inactivation of the NF-kB survival
pathway (see earlier), its effect on the sensitization of hepa-
tocellular carcinoma to hypoxia and chemotherapy deserves
further investigation (Fig. 15). Regarding this, we have ob-
served that the transfection of human hepatocarcinoma cells
with GD3 synthase, the enzyme that synthesizes GD3 from
GM3, inactivates the Src–NF-kB pathway translating into the
sensitization to hypoxia (Lluis et al., unpublished data). Thus,
GD3, in addition to its ability to prevent the activation of
NF-kB by the classic pathway through IkB degradation (60),
also is efficient in disabling its activation through the non-
canonic pathway involving phosphorylation of IkB at tyro-
sine residues.
Another key feature of tumorigenesis is the deregulation
of cholesterol metabolism, which is reflected by the desen-
sitization of hydroxymethylglutaryl-CoA reductase (HMG-
CoAR) to inhibition by sterols, and by the continued
cholesterol synthesis in growing solid tumors. Interestingly,
cholesterol synthesis requires molecular oxygen for the trans-
formation of squalene to cholesterol, and hypoxia has been
shown to mediate the degradation of HMG-CoAR (234). Al-
thoughmitochondria are cholesterol-poor organelles, another
level of deregulation of carcinogenesis is the recognized en-
richment of mitochondrial membranes in free-cholesterol
content (Fig. 11). Because cholesterol enrichment can ad-
versely affect mitochondrial functions (57, 189, 197), it is
conceivable that the accumulation of cholesterol within mi-
tochondrial membranes may account for or contribute to the
known mitochondrial dysfunction of cancer cells, underly-
ing theWarburg effect and dependence on aerobic glucolysis
for energy production (80). By using human and rat hepa-
tocellular carcinoma cell lines or the mitochondrial fraction
isolated from patients with hepatocellular carcinoma, a
dramatic increase in the levels of mitochondrial cholesterol
compared with untransformed cells was observed, which
translated into an increased membrane order parameter
(222). This outcome was accompanied by enhanced mito-
chondrial-chemotherapy resistance and was reversed by
either cholesterol extraction or fluidization of mitochon-
drial membranes. Moreover, given the role of StAR in reg-
ulation of mitochondrial cholesterol homeostasis (288), the
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FIG. 14. Mitochondrial reactive oxygen species in hyp-
oxic signaling. Mitochondrial ROS generation contributes to
cancer cell survival during hypoxia by a dual mechanism:
first, by stabilizing HIF-1a through the inhibition of the
oxygen-sensing enzymes prolylhydroxylase (PHD), which
requires oxygen, 2-oxoglutarate (2-OG), and Fe2þ, and sec-
ond, by inducing NF-kB activation by using a noncanonic
pathway involving the phosphorylation of IkB in tyrosine
residues through activation of the c-Src tyrosine kinase.
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downregulation of StAR in hepatocellular carcinoma cell lines
by siRNA reduced the net level of mitochondrial cholesterol,
increasing the susceptibility to mitochondria-targeted che-
motherapy. In line with these data, Lucken-Ardjomande (194)
recently showed that treatment of HeLa cells with U18666A, a
cholesterol transport–inhibiting agent that is used widely to
mimic Niemann-Pick type C disease, caused mitochondrial
cholesterol upregulation, resulting in a delay in the release of
Smac=Diablo and cytochrome c, as well as in Bax oligomeri-
zation and partial protection against stress-induced apoptosis.
Moreover, the inhibitory effect of cholesterol onmitochondrial
Bax activation was demonstrated in liposomes, and this effect
was exerted by a dual mechanism involving changes in
membrane order parameter and the decrease of Bax penetra-
tion into the membrane bilayer (222). Thus, by inhibiting
Bax-driven MOM permeabilization, cholesterol modulates
cell-death susceptibility. Furthermore, the potentiation of
hepatocellular carcinoma chemotherapy by squalene syn-
thase inhibition, which reduces cholesterol levels without
perturbing isoprenoid metabolism, validates the specificity of
cholesterol in chemotherapy resistance and revitalizes the
potential benefit of cholesterol downregulation in cancer
therapy.
An interesting contrast emerges in comparing the effect of
mitochondrial cholesterol loading occurring in SH and he-
patocarcinoma. Whereas in the former, mitochondrial cho-
lesterol accumulation plays a proapoptotic role, in the latter, it
acts in an antiapoptotic fashion, thus establishing a paradox in
cell-death regulation (Fig. 11). Intriguingly, the mitochondrial
cholesterol loading in SH results in mGSH depletion, whereas
hepatocarcinoma cells are able to maintain optimal mGSH
levels despite mitochondrial cholesterol accumulation by a
mechanism that is currently under investigation (Montero
et al., unpublished data).
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FIG. 15. Ganglioside GD3 enhances
apoptosis by suppressing the NF-jB–
dependent survival pathway. Scheme
showing NF-kB activation through the
classic (A) and the c-Src–dependent
pathways (B). GD3 is able to inhibit
the translocation of the p50=p65–NF-kB
subunits in both settings, resulting in
suppression of NF-kB–dependent gene
transcription and, thus, enhancing cell
death. The classic pathway (A) involves
the phosphorylation of IkB at serine res-
idues by the IkB kinase complex (formed
by NEMO, IKK1, and IKK2), followed by
IkB-ubiquitination and proteasomal deg-
radation, allowing translocation of the
p50=p65–NF-kB subunits to the nuclei. In
the noncanonic pathway (B), c-Src phos-
phorylates IkB at tyrosine residues, re-
sulting in its release and in translocation
of the p50=p65–NF-kB subunits to the
nuclei.
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G. Hepatic insulin resistance
One of the characteristic metabolic features of hepatic
steatosis is the resistance to the peptide hormone insulin,
which stimulates the uptake and storage of glucose and other
nutrients in skeletal muscle and adipose tissue while simul-
taneously repressing glucose efflux from the liver. Insulin
resistance occurs when a normal dose of the hormone is in-
capable of eliciting these anabolic responses, and the condi-
tion is a component of or a risk factor for many metabolic
diseases, including diabetes, hypertension, atherosclerosis,
and cancer. Obesity predisposes to the development of insulin
resistance, and several mechanisms have been proposed to
explain how increased adiposity antagonizes the insulin
stimulation of nutrient uptake and storage. First, increased
adipose tissuemay trigger the synthesis or secretion or both of
glucocorticoids or inflammatory cytokines such as TNF that
inhibit insulin action in peripheral tissues (143). Moreover,
excess lipids may be delivered to nonadipose tissues that are
not suited for fat storage (i.e., skeletal muscle and the liver),
leading to the formation of specific metabolites that directly
antagonize the insulin action (140). Hence, emerging evidence
suggests that nutrient excess is associated with an increase
in specific lipid-derived metabolites that inactivate signal-
ing intermediates and cause insulin resistance. However, the
mechanism by which specific lipid metabolites cause insulin
resistance is incompletely resolved. Although hepatic stea-
tosis is accompanied by hepatic insulin resistance, recent
studies provided evidence dissociating the degree of fat ac-
cumulation in the liver with the onset of hepatic steatosis
(220). Mice engineered to overexpress acyl-CoA:diacylgly-
cerol acyltransferase 2 (DGAT2), which catalyzes the final
step of triacylglycerol biosynthesis in the liver, exhibit mas-
sive hepatic steatosis with 20- to 30-fold higher triglyceride
levels, and yet they become insulin sensitive (220). These
findings clearly indicate that DGAT-mediated lipid accumu-
lation in the liver is insufficient to cause insulin resistance and
show that hepatic steatosis can occur independent of insulin
resistance.
Unlike the accumulation of triglycerides, recent data pro-
vided clear-cut evidence in favor of SLs accumulation, in
particular ceramide, in hepatic insulin resistance (140). Ex-
cessive levels of FFAs (saturated but not unsaturated), TNF-a,
and glucocorticoids, through different mechanisms, stimulate
the accumulation of the sphingolipid ceramide and various
ceramide metabolites (140). Increased ceramide synthesis in
response to excessive TNF, saturated FFAs, or glucocorticoids
is associatedwith a reduction of insulin signal transduction by
inhibiting PKB=Akt phosphorylation and activation. Cer-
amide promotes the dephosphorylation of PKB=Akt by pro-
tein phosphatase 2A (PP2A) and blocks the translocation of
PKB=Akt from the cytoplasm to the plasma membrane (264).
By using pharmacologic inhibitors and genetic mice deficient
in dehydroceramide desaturase, it was shown that the de novo
ceramide synthesis from saturated FFAs and glucocorticoids
plays a key role in hepatic insulin resistance (140). In addition
to this pathway of ceramide generation, recent evidence
showed a key role for ASMase in hepatic steatosis and insulin
resistance induced by high-fat feeding (74), thus pointing to
this pathway of ceramide stimulation as another contributing
factor in ceramide upregulation and hence in hepatic insulin
resistance. These data, coupled with the preceding findings
showing a role for ASMase in NASH, suggest that the phar-
macologic inhibition of this enzyme may be of relevance in
various forms of liver diseases, including the hepatic mani-
festation of the metabolic syndrome and associated comor-
bidities. Moreover, further studies are needed to investigate
the role of complex glycosphingolipids in hepatic insulin re-
sistance, as these lipids arise from ceramide in the Golgi and
have been shown to modulate the insulin response (330,
340). Moreover, because ceramidases regulate ceramide me-
tabolism and turnover by generating sphingosine, which
can undergo different metabolic fates (Fig. 7), their role in
insulin resistance and hepatic steatosis also merits further
research.
Finally, protein tyrosine phosphatases (PTPs) are redox
regulated by ROS generation and are known to modulate
multiple signaling pathways (48, 213). Because tyrosine phos-
phorylation of insulin receptor is essential for signaling, its
regulation at this step by PTPs modulates insulin signaling.
Insulin stimulation in hepatic cell lines resulted in the rapid
and transient oxidation and subsequent inhibition of PTP1B
and TC45, enhancing phosphorylation of Tyr-972 in the
insulin-receptor b-subunit. Tyr-972 is an important residue
for the recruitment of insulin-receptor signaling-1 and the
activation of PKB=Akt. Thus, the role of PTPs in obesity and
insulin resistance deserves further investigation.
H. Drug-induced liver injury
Because of its fundamental role in metabolism, the liver is
a primary target of xenobiotic biotransformation. The hepa-
totoxic potential of common therapeutic drugs, herbal rem-
edies, or dietary supplements is widely recognized as an
increasing health problem. Drug-induced liver injury reflects
hepatocyte stress and death, which can arise directly by par-
ent drugs or toxic metabolites, and it is modulated by a
number of factors, including nutritional status and genetic
determinants. One of the best and most relevant examples of
drug-induced liver injury is acetaminophen-induced hepato-
toxicity. Acetaminophen (N-acetyl-p-aminophenol, APAP) is
a widely used analgesic, and it is considered to be safe when
taken at therapeutic doses. However, at higher doses or under
conditions that determine enhanced susceptibility to APAP
(e.g. alcohol feeding), hepatocellular death and subsequent
liver injury ensues. APAP is metabolized in vivo by cyto-
chrome P450, particularly cytochrome P450 2E1 (CYP2E1) to a
toxic metabolite, N-acetyl-p-benzoquinone imine (NAPQI),
which can attach and covalently modify proteins (216, 232). A
primary line of defense against NAPQI is through GSH con-
jugation that results in its depletion, especially if GSH con-
sumption by NAPQI is not matched by synthesis. Although
APAP can decrease GSH in both cytosol and mitochondria,
the kinetics of GSH depletion in hepatocytes exposed to
APAP showed that the depletion of mGSH preceded that
of cytosol GSH (313), indicating the relevance of this pool
of GSH in the hepatotoxicity of APAP. Interestingly,N-acetyl-
m-aminophenol (AMAP), a nonhepatotoxic regioisomer of
APAP, depletes cytosol GSH but not mGSH (141). Like
that of many other drugs, APAP cytotoxicity in hepatocytes
is mediated through mitochondrial membrane permea-
bilization through MPT, as described earlier. Thus, agents
that block MPT, such as cyclosporin A, protect hepatocytes
against APAP-induced cell death. However, despite MPT and
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cytochrome c release, necrosis rather than apoptosis is the
predominant mode of cell death induced by NAPQI. This
outcome likely reflects insufficient ATP levels due to impaired
mitochondrial oxidative phosphorylation, together with cas-
pase inhibition by the redox change and ROS overgeneration,
which prevent the apoptotic phenotype.
A novel mechanism of APAP hepatotoxicity involves JNK
activation. APAP induced sustained JNK activation and
necrosis that was prevented by a synthetic JNK inhibitor
(SP600125) both in isolated hepatocytes and in intact mice
(125). Although jnk2 seems to play a more important role
in mediating APAP toxicity than jnk1, full protection was
achieved by silencing of both jnk1 and jnk2 (125). However, it
remains unknown whether the protective strategy of jnk1=2
silencing in APAP hepatoxicity is due to their downregula-
tion in hepatocyte versus hematopoietic cells. In contrast to
JNK activation, the role of innate immunity, Kupffer cells,
neutrophils, and natural killer or natural killer T cells in
APAP-mediated hepatotoxicity remains controversial (150).
However, the fact that isolated mouse hepatocytes can be
killed by APAPwith amechanism similar to the one observed
in vivo supports a limited role of innate immunity in APAP
hepatotoxicity. Nevertheless, although the participation of in-
nate immunity may account for the individual susceptibility
to APAP-induced liver injury, the primary antidote for APAP-
induced hepatocellular death is still N-acetylcysteine to boost
hepatic GSH stores and mitochondrial function to keep up
with NAPQI detoxification.
IX. Conclusions
The cumulative evidence provided over the years clearly
supported a role for ROS and oxidants as important factors in
many different pathologic processes, including liver diseases.
The foundation for this role in pathophysiology derives from
the reactivity of these reactive species with different cellular
components such as lipids or DNA, and,more especially, with
proteins because of the presence of cysteine residues. In most
cases, as shown in cell-free or in in vitro cell systems, ROS and
oxidant generation can perturb the functions of these vital
cellular constituents, resulting in cell dysfunction or death. As
a consequence, treatment with antioxidants has been shown
to be beneficial under these controlled conditions. Unfor-
tunately, the expectation of this translational application to
human disease has not been fulfilled, as most clinical trials
with antioxidants have been disappointing, with no effective
antioxidant drug being available for widespread use today.
Although this could be viewed as an indictment of the free
radical theory, it may well reflect our limitation in the un-
derstanding the complex interactions=mechanisms of oxi-
dant and antioxidant actions in designing effective therapies.
Moreover, some antioxidants, such as ascorbate, can exhibit a
dual nature, acting as an antioxidant or oxidant, depending
on the redox environment. In addition to our continued efforts
in basic research, to better understand the chemistry and bi-
ology of free radicals and their counterparts, we need larger,
well-designed, randomized, double-blind, controlled trials to
test the role of antioxidants in disease outcome. Moreover,
ROS and oxidants may exhibit a dual life, acting as friends or
foes, depending on factors that control their site, specificity, or
magnitude of generation. A sound example of the unwanted
effects of using antioxidants centers on aging research with
the hormetic control of eukaryotic life span, in which an in-
crease in ROS leads to a secondary development in stress
defense, resulting in reduced net stress levels. Thus, as our
understanding about the mechanisms, nature, and sites of
ROS generation and their impact on biologic targets increases,
it will likely translate into better management of the use of
antioxidants and ROS scavengers in the therapy for liver
diseases.
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Abbreviations Used
2-OG¼ 2-oxoglutarate carrier
4-HNE¼ 4-hydroxynonenal
AIF¼ apoptosis-inducing factor
AngII¼ angiotensin II
ARE¼ antioxidant responsive element
ASH¼ alcoholic steatohepatitis
ASMase¼ acidic sphingomyelinase
DCF¼dichlorofluorescein
DGAT2¼ acyl-CoA:diacylglycerol acyltransferase 2
DIC¼dicarboxylate carrier
ER¼ endoplasmic reticulum
GCL¼ glutamate cysteine ligase
GGT¼ g-glutamyl transferase
GR¼GSH reductase
Grx¼ glutaredoxin
GSH¼ reduced GSH
GSHPx¼GSH peroxidase
GSSG¼ oxidized GSH
GST¼GSH-S transferase
mGSH¼mitochondrial GSH
MIM¼mitochondrial inner membrane
MOM¼mitochondrial outer membrane
MPT¼mitochondrial permeability transition
NASH¼nonalcoholic steatohepatitis
NSMase¼neutral sphingomyelinase
PP2A¼protein phosphatase 2A
Prx¼peroxiredoxin
PSH¼ reduced proteic SH
PSSG¼mixed GSH and proteic SH disulfide
PSSP¼proteic disulfide
PUFA¼polyunsaturated fatty acid
RCS¼ reactive carbonyl species
RNS¼ reactive nitrogen species
ROS¼ reactive oxygen species
SAM¼ S-adenosyl-l-methionine
SH¼ steatohepatitis
SH¼ thiol
SLs¼ sphingolipids
SMase¼ sphingomyelinase
SOD¼ superoxide dismutase
SPT¼ serinepalmitoyl transferase
Srx¼ sulfiredoxin
StAR¼ steroidogenic acute regulatory polypeptide
TLR¼Toll-like receptor
TMRE¼ tetramethylrhodamine methyl ester
TR¼ thioredoxin reductase
Trx¼ thioredoxin
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